BACKGROUND: Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) are risk factors for cardiovascular disease (CVD). It is unclear whether pulse pressure (PP) and mean arterial pressure (MAP) provide additional information in predicting CVD risk. We analyzed data from the Physicians' Health Study enrollment cohort to evaluate the relationship between SBP, DBP, PP, MAP and the risk of CVD mortality in men. METHODS: In a prospective cohort design, 59,687 normotensive men free of CVD and cancer completed a baseline questionnaire. Data were collected on coronary risk factors including self-reported SBP, DBP, PP (SBP-DBP) and MAP (2/3SBP + 1/3DBP). Using the National Death Index, death certificates were obtained and ICD codes were used to identify cases of CVD death. Relative Risks (RRs) and 95% confidence intervals were computed using Cox proportional hazards models adjusting for coronary risk factors. RESULTS: During a mean follow-up of 5.5 years, 588 men (median age = 67.3) died from CVD. At baseline, mean SBP was 125.0 11.3, DBP was 78.0 7.0, PP was 47.0 8.9 and MAP was 93.7 7.6. The corresponding multivariate RR's of CVD death for 10 mm Hg increments of SBP, DBP, PP and MAP were 1.22 (1.14±1.30), 1.14 (1.01±1.29), 1.23 (1.14± 1.33 ) and 1.28 (1.14±1.42) . We then considered the joint effects of combinations of BP measurements in the multivariate model (Table 1) . CONCLUSION: All four BP components were each independent predictors of CVD death. When considered in combination with any of the other three BP measures, SBP was the only BP measurement that consistently remained a significant predictor. This suggests that SBP may be the most informative blood pressure measurement in the prediction of CVD death among initially healthy normotensive men.
Comparison of RR's in the combined multivariate models (10 mm Hg increments) BACKGROUND: If complementary or alternative medicine (CAM) is used instead of, rather than in addition to traditional treatments, the latter might be delayed. Recent studies have shown 31% of cancer patients utilize a form of CAM. We explored whether CAM use reduced the likelihood of receiving traditional therapy. METHODS: A CAM questionnaire was mailed to participants in the Ambulatory Care Quality Improvement Project, a randomized trial involving 7 VA outpatient centers. Subjects who returned a CAM questionnaire and were diagnosed with cancer during the last 1.5 years of the trial were studied. Diagnosis and treatment were both ascertained from computerized inpatient and outpatient records. Medicare data were available for those over 65. Hazard ratios for treatment (HR) were calculated from Cox models for those who received treatment more than 14 days after diagnosis. Subjects for whom no definitive treatment was observed were censored. RESULTS: There were 16,640 subjects who completed and returned a CAM questionnaire; 823 (5%) developed incident cancer and fit inclusion criteria. Fifty percent (n = 408) of the subjects reported some use of CAM at any time in the past, with 241 (30%) reporting use within the past year. There were 704 subjects who did not receive therapy in the first 14 days after diagnosis of cancer, with 160 definitive treatments observed before the end of the study. Those using CAM within the past year did not have a decrease in the likelihood of therapy (age adjusted HR 0.82, 95% CI 0.6±1.2) compared with patients who never used CAM. Those who had ever used CAM were 35% less likely to receive traditional therapy (age adjusted HR 0.65, 95% CI 0.5±0.9; p = 0.01) compared with those who never used CAM therapy. CONCLUSION: Ever using CAM but not current use was associated with a lower risk of receiving traditional therapy among veterans, suggesting users of CAM may be less likely to accept traditional therapy.
OUTPATIENT PHARMACY CARE AND HIV-1 RNA RESPONSE AMONG PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. E. Castillo 1 , A. Palepu 1 , A. Beardsell
The largest changes were in the use of prescription NSAIDs for acute pain and opioids for chronic pain. Use of higher potency opioids (e.g. hydrocodone, oxycodone, morphine) for chronic pain tripled from 3% to 9% of visits. In addition to opioids, tramadol, a new drug with opiate-like characteristics was prescribed at 3% of chronic pain visits in 2000. CONCLUSION: In spite of the increased attention to pain treatment, there has not been a substantial increase in office visits for musculoskeletal pain complaints. The threshold for prescribing NSAIDS and opioids, however, has decreased. BACKGROUND: Slowed heart rate recovery (HRR) following peak exercise has been shown to be an independent predictor of all-cause mortality in healthy adults as well as in patients with documented heart disease. To date, there are no studies specifically evaluating the relationship between HRR, cardiac outcomes, and mortality in patients with type 2 diabetes mellitus (T2DM). The current study examines this relationship over a 5-year follow-up period. METHODS: Subjects consisted of T2DM patients enrolled in the Appropriate Blood Pressure Control in Diabetes trial. Charts were reviewed retrospectively and all patients who performed symptom-limited Bruce protocol exercise treadmill tests at baseline (n = 890) were included in the analysis. Utilizing existing literature, abnormal HRR at 1 minute was defined as a decrease of 12 beats per minute (bpm) or less. A chi-square test was used to evaluate the relationship between the published cutoff for abnormal HRR and both cardiovascular and all-cause mortality. Chronotropic incompetence (C.I.), defined as failure to acheive 85% of agepredicted peak maximal heart rate, was evaluated along with HRR in a mulitple logisitc regression model for their relationship to all-cause and cardiovascular mortality. RESULTS: Of 871 patients with 1-minute HRR data, 188 had an abnormal HRR and 144 had C.I. All-cause mortality among patients with an abnormal HRR was 11.7% vs. 6.3% among patients with a normal HRR (p = 0.01), and cardiovascular mortality was 5.9% vs. 3.5% in patients with an abnormal HRR versus a normal HRR respectively (p = 0.15). Patients demonstrating C.I. had an OR for all-cause mortality of 2.28 (95% CI 1.3±4.1, p = 0.006) and an OR for cardiovascular mortality of 3.0 (95% CI 1.3±6.8, p = 0.009). CONCLUSION: In the present study of patients with T2DM, HRR at 1 minute after maximal exercise was a significant independent predictor of all-cause mortality. HRR is less predictive of cardiovascular mortality in this group. These findings suggest that although there are higher event rates among those with HRR of less than 12 bpm, this specific cutoff may not be relevant for a population with T2DM. C.I. is a stronger predictor of both all-cause and cardiovascular mortality in this population. Johns Hopkins University, Baltimore, MD (Tracking ID #76261) BACKGROUND: As the prevalence of chronic hepatitis C rises, general internists will need to be increasingly familiar with alternate interferon-based combination therapies such as interferon (IFN) and amantadine. We performed a systematic review of the literature to assess the efficacy of the combination of amantadine and standard IFN compared to standard IFN alone in patients with chronic hepatitis C. METHODS: We searched 8 electronic databases from January 1996 to March 2002. We identified additional studies by searching for references in pertinent studies, recent journals and by questioning experts. Studies were eligible for review if they were randomized controlled trials (RCT), reported original human data, and used virological or histological outcome measures. Meta-analysis was performed using the Mantel-Haenszel and Der Simonian and Laird Methods after checking for qualitative and statistical heterogeneity of the studies. To assess for possible publication bias we ran the analysis with and without studies reported only in abstracts. RESULTS: Out of 30 RCTs in treatment nay Ève individuals with chronic hepatitis C, 5 addressed the efficacy of IFN and amantadine, with a total of 888 patients. Mean age ranged between 38 and 48 years, and 26±71% of patients had hepatitis C genotype 1. Study quality varied with only two trials being double-blinded and one study reporting on allocation concealment. The rate of sustained virological response (SVR) ranged from 10±29% in the combination group, and from 14±22% in the control group. A meta-analysis of the 5 studies demonstrated a 4% absolute risk difference (95% confidence interval (CI), À;3 to12%) in SVR in treatment naõ Ève individuals receiving standard IFN with amantadine compared to standard IFN monotherapy. Meta-analysis including an additional 4 abstracts demonstrated a 2% absolute risk difference (95% CI, À4 to 8%). There was no significant statistical heterogeneity with either meta-analysis (p > 0.05). In 5 studies of IFN and amantadine in previous IFN nonresponders, standard IFN with amantadine was no better than either standard IFN alone or IFN and ribavirin in achieving an SVR, but triple therapy with standard IFN, amantadine, and ribavirin achieved an increase in SVR in one small study (N = 60). These studies were not pooled secondary to qualitative heterogeneity. CONCLUSION: We conclude that amantadine adds little to the efficacy of standard interferon in the treatment of chronic hepatitis C. BACKGROUND: End-stage renal disease (ESRD) has had a considerable impact on the functional status and quality of life (QoL) as perceived by patients and has been the subject of intensive research for more than 2 decades. The purpose of this study was to examine the effect of psychosocial factors on a population with ESRD from all socioeconomic strata in an urban setting from Chennai, India. METHODS: The study was based upon a survey consisting of about 100 questions, spanning numerous aspects of the patient's day-to-day living including chronic pain, sexual function, sleep disturbances, and cognitive function. The questions were based upon modifications of numerous available kidney quality of life dialysis instruments, cognitive function indices, and sleep assessment instruments. RESULTS: There were 35 males and 18 females in the study. The mean age of the patients was 49.5 years. The mean time on hemodialysis was 32.8 months. In their overall health rating, on a scale of 1 (worst) to 10 (best), the patients mean score was 3.63; the mean rating compared to one year ago was slightly better at 4.09. Dialysis related issues: The most common complaints included fatigue, lack of strength, excessive thirst, dry mouth, and sleeping trouble. 19% of patients reported difficulty complying with the food restrictions, however only 9% reported difficulty with fluid restrictions. Psychosocial issues: Many patients reported significant social issues; 62.2% reported difficulty enjoying time with family, 20.7 % reported difficulty with traveling on a day to day basis , and 83% reported difficulty lifting heavy weights they were able to lift before. 28% reported having decreased perception about their personal appearance, 38% reported a lack of time due to thrice weekly dialysis, 68% reported difficulties being able to squat to perform their ADL's. Up to 50% of patients reported mild to moderate cognitive impairment, and several males in the study reported sexual dysfunction. Up to 40% of the patients reported significant sleep disturbances specifically an inability to fall asleep or being awoken in the middle of their sleep. Greater than 50% of patients reported feeling motivated and informed about dialysis. CONCLUSION: The incidence of depression, sleep disturbances, and sexual dysfunction are both under-recognized and under-treated in chronic hemodialysis patients, regardless of the care setting.The expectations of the standards of care will increase, as our knowledge of the psychosocial implications of chronic disease continue to be elucidated, and more data becomes available. BACKGROUND: Although excessive alcohol intake may alter patient behavior and thus affect patient compliance, little is known about the effect of alcohol consumption on diabetes selfcare. We sought to determine the association between patient reports of alcohol consumption and diabetes care quality and adherence to diabetes self-management. METHODS: We analyzed data from a nationally representative population-based survey, the 2001 Behavior Risk Factor and Surveillance System (BRFSS). We included 5322 adults (age>17) with a reported diagnosis of diabetes. Based on self-reported average alcohol consumption in the past 30 days, we categorized participants into the following groups: abstainers (none), low-level drinkers (drinks/day: >1 for women; >2 for men), and hazardous drinkers (drinks/day: >1 for women; >2 for men). A diabetes-specific BRFSS module was used to obtain clinical characteristics and preventive care practices from respondents with diabetes. Main analyses compared hazardous drinkers to all other diabetics (abstainers and low-level drinkers). RESULTS: Two percent (n = 95) of individuals with diabetes reported hazardous alcohol consumption, 29% reported low-level alcohol consumption, and 69% were abstainers. Hazardous drinkers were more likely to be male and employed compared to low-level drinkers or abstainers (p < 0.05). Current smoking was more common among hazardous drinkers compared to abstainers and low-level drinkers (40.3% vs. 16.0%, p < 0.001). Hazardous drinkers were more likely than other diabetics to report infrequent glucose self-monitoring (less often than weekly) (29% vs. 17%, p = 0.03) and lack of participation in a diabetes education class (64% vs. 46%, p = 0.04). Hemoglobin A1C monitoring, annual foot and eye examinations, and self-foot examinations varied little across alcohol consumption categories. Hazardous drinkers were more likely than other diabetics to report infrequent glucose selfmonitoring (OR = 2.4, 95%CI: 1.1±5.0) and having not participated in a diabetes education class (OR = 2.3, 95%CI: 1.0±5.5), after controlling for age, gender, education, income, race, health care coverage, years since diabetes diagnosis, and insulin use. CONCLUSION: Hazardous alcohol consumption among diabetic patients may be associated with poorer adherence to diabetes self-management, particularly glucose self-monitoring and participation in diabetes education. Primary care providers should consider screening for hazardous alcohol consumption to identify patients at risk for non-adherence to some diabetes self-care behaviors. Hispanics, 81 of whom were Spanish speaking), the prevalence of PAD was 16.6%. Convergent validity evidence was strong for both non-Spanish speaking and Spanish speaking patients; the correlations between the WIQ subscales and the SF-36 physical health measures were the strongest ranging from 0.36 to 0.66; all were significant at P < .01. For Spanish speaking patients, the correlation between walking distance and physical health measures ranged from 0.44 to 0.74 (P < .01 for all correlations). For both groups the correlations of walking speed and stair climbing with all physical health measures had similar values and ranged from 0.36 to 0.72 (P < .01 for all correlations). The correlations of walking distance, speed, and stair climbing with emotional health measures of the SF-36 ranged from 0.29 to 0.49 for non-Spanish speaking patients (P < .01 for all correlations). For Spanish speaking patients, the correlations of walking ability with emotional health measures ranged from 0.18 to 0.44; all were statistically significant at P < .05. CONCLUSION: The WIQ scores correlated well with SF-36 components for both nonSpanish speaking and Spanish speaking patients. The strongest correlations were between the WIQ and the SF-36 physical health measures. Our findings suggest that our translation process did not limit our ability to capture valid data. , 2) pharmacy data captured all medications used to treat DM (meds), and laboratory data was used to identify patients with 3) HbA1c >7 mg/dL or 4) two random blood glucoses > 200 mg/ dL. Chart review was conducted to verify diagnoses of type 2 DM (gold standard) and exclude cases of type 1 DM. RESULTS: 86 cases of type 2 DM were identified among a population of approximately 1600 HIV-infected patients. Because the prevalence of DM among HIV-infected patients is low, small decreases in specificity resulted in substantial decreases in PPV. Used alone, ICD-9 diagnosis codes provided the highest level of sensitivity. Requiring that a patient have both an ICD-9 code and a diabetic medication resulted in the the highest specificity and PPV, but significantly lowered the sensitivity of the method. CONCLUSION: Computerized data from clinical information systems can be used to identify HIV-infected patients with type 2 DM. The optimal method for identifying DM cases for a particular study will depend on the goals of the selection procedure. BACKGROUND: Controversy surrounds the growing number of popular diet plans targeting weight loss and cardiac risk reduction. Data on the relative effectiveness of these strategies are limited, especially under conditions of realistic dietary adherence. We conducted a randomized clinical trial evaluating the effectiveness of 4 popular diet strategies for weight loss and cardiac risk reduction. METHODS: One-hundred sixty adults with excess body mass and one or more metabolic cardiac risk factor were randomized to 1 of 4 dietary treatment strategies restricting either total fat (Ornish diet), total carbohydrates (Atkins diet), saturated fat and insulinogenic carbohydrates (Zone diet), or total calories (Weight Watchers diet). During the first 2 months of the study, subjects participated in 4 one-hour group sessions during which a dietitian and physician reviewed the rationale, recipes, meal plans and supplemental reading materials appropriate for the assigned strategy. After 2 months of intensive intervention aiming for maximum adherence, participants were asked to determine their own level of diet plan adherence for the following 10 months. Primary outcomes were changes in body mass index and Framingham cardiac risk score at 12 months. Secondary outcomes were changes in blood pressure, fasting serum lipids, glucose, glycohemoglobin, insulin, urine C-peptide, and renal function. Dietary adherence was assessed by 3-day diet diaries, urine nitrogen and ketones, and monthly telephone surveys. Data collection was completed in January 2003. RESULTS: All 160 participants were recruited from the Greater Boston area. At baseline, median age was 50 years (range 23 to 73), 75% were Caucasian, 50% were male, 94% had dyslipidemia, 46% had elevated blood pressure, 47% had hyperglycemia or type II diabetes mellitus, and 6% had known coronary artery disease. Mean body mass index was 34.7 (SD 3.9) kg/m 2 , and mean Framingham score for 10-year risk of a coronary event was 9.1% (SD 7.4%). Diet records at baseline were consistent with the average American diet, with a mean daily intake of 2059 calories; 46% from carbohydrates, 35% from total fat, 12% from saturated fat, and 18% from protein. Final results for weight loss and cardiac risk factor reduction will be available at the time of the SGIM conference. CONCLUSION: This randomized trial will provide much needed effectiveness data regarding popular diet strategies. It evaluates a broader range of popular diets and a longer follow-up period than any previously reported study. The results will have the potential to substantially validate or challenge conventional and alternative dietary approaches to cardiac risk and body fat reduction. BACKGROUND: Can a Peak oxygen consumption measurement during symptom limited stress testing be an independent predictor of mortality and morbidity in a stable coronary patient? METHODS: 164 consecutive coronary patients for cardiac evaluation had undergone symptom-limited stress testing using standard ramp protocol and simultaneous peak oxygen uptake was measured using Medgraphics CPX machine in an office setting RESULTS: Patients in this study were followed up prospectively for an average period of 3 years. Of the 164 patients, 9 patients were lost for follow up. 18 patients were found to have VO2 (Oxygen uptake) of 14 ml/kg/min or less out of which 6 expired, 3 refused intervention, and 9 had underwent either percutaneous transluminous coronary angioplasty or coronary artery bypass graft. Of the remaining 137 patients, only 6 needed Angioplasty, 3 expired due to various causes, 3 patients needed coronary bypass graft in the following three years. Various studies have shown that peak oxygen uptake is an independent predictor of cardiac and all cause mortality in patients waiting for cardiac transplant. VO2 has a close linear relationship with cardiac output, which in turn to myocardial damage and or ischemia. Peak oxygen consumption can be safely measured in an office setting in stable coronary artery disease patients. There is more than 80% chance of MACE (Major adverse cardiac event) in patients who only reach peak VO2 of less than 14 ml/kg/min. Cardiac and all cause mortality and morbidity is significantly worse in patients in whom VO2 is less than 14ml/kg/minute. CONCLUSION: Measurement of Peak VO2 during symptom limited exercise stress testing can be used as an independent prognostic indicator for long-term morbidity and mortality in coronary disease. BACKGROUND: Hypochondriacal worry (HC) is characterized by medically unexplained physical symptoms, bodily preoccupation, disease phobia, and the conviction that one has a disease despite reassurance. Significant worry leads to distress, impairment in functioning, and increased primary care utilization. The objective of this study was to compare persons with HC who had doctor-confirmed medical illness to those with HC who did not have illness. METHODS: Trained interviewers using a computer-assisted telephone interviewing system conducted surveys of individuals aged 18±64 years residing in the continental United States. Subjects were screened with the question``During the past 12 months, have you had a period of one month or more when you worried most of the time about having a serious illness?'' The survey included items assessing demographics, medical conditions, psychiatric comorbidity, domains of illness worry and medical utilization. Univariate and multivariate statistics were calculated to compare factors associated with illness worry. RESULTS: The overall response rate was 55%. 123 subjects met the screening criterion for HC. The one-year prevalence was 7%. Most (81%) subjects sought medical care for their worry, with 54% (n = 67) reporting that a doctor had confirmed the presence of the illness of concern; 46% (n = 56) did not have the illness they were worried about. Differences were found between those with the illness they worried about and those without. Those with the illness were older, had more depression, a longer period of worry, and more severe worry. Worriers with illness more frequently told doctors about their concern (81% vs. 66%), and had``little'' or``not at all'' reassurance (28% vs. 9%). Both groups reported seeing a doctor regarding the feared illness (90% ),``some'' or``a lot'' of distress (76% and 64%), and``some'' or``a lot'' of interference with activities (67% and 38% of all first mental health claims. Urban and rural subjects had a similar likelihood of receiving this diagnosis. Among rural dwellers, 1/3 of all AD diagnoses were made by PCPs (33% rural vs. 25% urban). Urban dwellers were more likely than rural dwellers to be hospitalized for the AD (0.25 vs. 0.16 hospitalizations, P < 0.0001), have more mental health visits (7.5 vs. 5.6 visits, P < 0.0001), and receive psychotherapy (38% vs. 34%, p < 0.0001). 39% of all AD patients later filed a claim for another mental health diagnosis, most commonly a mood disorder (50%), anxiety disorder (19%), or substance disorder (8%). A small proportion of patients was referred to mental health providers (MHPs) (20% urban; 15% rural) and saw MHPs a median of three months after initial AD diagnosis. In half of these cases, the diagnosis remained the same, over 1/3rd were changed to mood disorders, and 7% to anxiety disorders. CONCLUSION: PCPs frequently diagnose AD. Although AD rarely resulted in hospitalization, outpatient utilization was substantial. Urban patients were more likely to receive mental health services. Mood and anxiety disorders accounted for the majority of follow-up diagnoses. BACKGROUND: Fatigue, a symptom highly prevalent in clinic and population-based studies, is difficult to measure. Much of this difficulty stems from the multidimensional nature of fatigue, which may be described as a feeling state and by using neurocognitive parameters as well as physiologic measures. In a community-based survey, we previously determined that respondents could differentiate among physical, mental and emotional fatigue, and that each of these had a negative effect on quality of life. We wanted to determine if fatigue might also have a positive component. That is, could one be``tired but happy'' and did this improve quality of life? METHODS: Using a random-digit dialing, statewide, telephone survey, we administered the MOS-20 measure of health related quality of life indicators to 661 adults. Respondents were asked how often they had experienced physical, mental and emotional fatigue during the previous one month. They were also asked about the experience of being``tired but happy''. Quality of life measures were subscales from the MOS-20: physical, social and role functioning, mental health, health outlook and pain. Open-ended comments were solicited. RESULTS: Among our respondents physical, mental, and emotional fatigue occurred in frequencies that followed a normal distribution, but the symptom of being``tired but happy'' did not. Approximately 10% of respondents denied ever feeling``tired but happy''. The remainder were evenly divided in reporting this symptom, with approximately 20% reporting frequencies in each of four categories: 1±2 times per month, once per week, twice per week, and every day. After controlling for age, gender, education, and rural/urban residence, feeling`t ired but happy'' was found to be positively correlated with the scores on five of the MOS subscales, indicating better quality of life. This was especially true for respondents who reported high levels of physical or emotional fatigue. Open-ended comments stressed the importance of the context in which fatigue was experienced. CONCLUSION: In addition to the dimensions of fatigue associated with a poorer quality of life, there is an aspect of fatigue associated with improved quality of life. The state of being`t ired but happy'' had a positive impact on quality of life and improved the level of functioning, especially in the setting of increased physical or emotional fatigue. We conclude that the context in which fatigue is experienced is important in understanding its impact on quality of life. BACKGROUND: Major depression (MD) is associated with increased healthcare utilization, costs, and poor health outcomes. Prevalence of MD is higher in patients with chronic medical conditions but precise estimates and correlates of MD in this group are poorly characterized. Data from the 1999 National Health Interview Survey (NHIS) was analyzed to estimate the prevalence and correlates of MD among patients with common chronic medical conditions. METHODS: 30,022 adults were surveyed in 1999. Eight chronic medical conditions (n = 11465) were selected based on self-report including diabetes (DM) (n = 1810), hypertension (HTN) (n = 7363), cardiovascular disease (CVD) (n = 3488), and chronic obstructive pulmonary disease (COPD) (n = 1663), any cancer (CA) (n = 2035), stroke (CVA) (n = 727), end-stage renal disease (ESRD) (n = 443), and chronic liver disease (CLD) (n = 297). Comorbidity was defined as having 1, 2, or 3+ chronic conditions. MD was assessed with the Composite International Diagnostic Interview Short Form (CIDI-SF), which is a valid and reliable diagnostic interview with classification accuracy of 93% for DSM IV MD. Prevalence of MD across conditions, among people with 1+ chronic conditions, and by comorbidity was determined. Multiple logistic regression was used to determine independent correlates of MD in people with 1+ chronic conditions. Covariates included age, sex, ethnicity, education, income, employment, marital status, perceived health status, smoking status, and comorbidity. STATA was used for statistical analyses to account for the complex sampling design of the NHIS. RESULTS: Weighted prevalence of MD was as follows: DM (9.3%), HTN (8.3%), CVD (9.8%), COPD (16.3%), any CA (9.1%), CVA (12.3%), ESRD (17.6%), CLD (19.0%), and 1+ chronic conditions (9.0%). Weighted prevalence of MD by comorbidity was as follows: none (4.8%), 1 (7.8%), 2 (10.4%), and 3+ (12.5%). Controlling for covariates, whites (OR 1.3), 18-64 year olds (OR 5.2), women (OR 1.9), people with income $20,000+ (OR 1.3) the unemployed (OR 1.3), the unmarried (OR 1.9), those with perceived poor health (OR 3.7), and smokers (OR 2.0) were more likely to have MD. Odds of MD increased with increasing comorbidity (OR: 1 = 1.8, 2 = 2.9, 3 += 3.1). CONCLUSION: Prevalence of MD ranged from 8.3% to 19.0% in patients with chronic medical conditions. Odds of MD increased with increasing comorbidity. Internists should consider the diagnosis of MD in primary care patients with multiple chronic conditions. BACKGROUND: While the impact of multiple sclerosis (MS) can be substantial in terms of quality of life, life expectancy is similar to age-matched controls, highlighting the appropriateness of delivering both MS-related and general preventive care to MS patients.
HEART RATE RECOVERY AS
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Little is known about the receipt of either by MS patients and how such receipt differs by physician specialty. METHODS: Using a cohort of continuously enrolled HMO patients with MS aged 18 and over receiving care in 1997 from a primary care physician (PCP), neurologist or both (n = 325) we describe receipt of MS and general preventive care by physician specialty. MS-related care evaluated included the receipt of beta interferon, MRI testing, and referral to urology, behavioral health, occupational therapy, and physical therapy. General preventive health service receipt evaluated included pneumococcal vaccine, cholesterol screening, and, among female patients, Papanicolaou smear and mammography receipt. Study data were compiled from automated databases, medical records, and patient surveys. The relationship of service receipt to specialty of physician(s) seen (PCP only, neurologist only, vs. both as well as any PCP vs. neurologist only and any neurologist vs. PCP only) was assessed using unadjusted and adjusted generalized estimating equation approaches.
RESULTS: During the study year, over one third of patients saw only a PCP (21%) or only a neurologist (15%), while the remainder (64%) sought care from both a neurologist and PCP.
Patients seeing a neurologist were most likely to receive each of the 6 MS care components assessed, however only 2 such differences were statistically significant. Those seeing any neurologist vs. PCP only were more likely to receive beta interferon (30.6 vs. 14.3%, p = 0.02), and those seeing a neurologist only vs. PCP only were more likely to receive ophthalmology care (26.5 vs. 18.4%, p = 0.02). After controlling for differences in patient characteristics, no statistically significant differences were found in receipt of MS care by physician specialty.
Patients seeing a PCP during the year were more likely to receive each of 4 general preventive care components assessed and when differences could be tested (i.e., when zero cell counts did not exist), these remained statistically significant in adjusted models. BACKGROUND: Intracranial hemorrhage (ICH) is the most feared complication associated with warfarin therapy. Despite strong evidence favoring anticoagulation for atrial fibrillation (AF), fear of ICH prompts many providers to withhold anticoagulants or target low INRs, especially in the elderly. Prior studies of ICH and anticoagulant intensity used the now outdated prothrombin time ratio, were not restricted to AF patients, and did not assess for concomitant aspirin use. We examined the relationship between ICH and International Normalized Ratio (INR) in patients with AF. METHODS: We conducted a case-control study at the Massachusetts General Hospital, searching the billing system for all patients with ICD-9 diagnoses of ICH and atrial fibrillation. Cases were included if they developed a radiographically confirmed ICH while taking warfarin. We matched each case to six control AF patients from our anticoagulation clinic, and reviewed medical charts for clinical information including age, INR, and aspirin use. Conditional logistic regression was used to determine the independent factors associated with ICH. RESULTS: We identified 107 cases of warfarin-associated ICH and 642 control patients, making ours the largest ICH study to date in AF patients. Cases were older than controls (mean age 78 vs. 74 years, p < 0.01) and had higher INRs (mean INR 3.3 vs. 2.5, p < 0.01). There were no differences in concomitant aspirin plus warfarin use (20% in both cases and controls). The odds of ICH did not significantly increase until after age 85 years (referent group 70±74 years) and at INRs greater than 3.5 (referent group 2.0±2.5). Although elevated INRs were associated with higher ICH risk, most hemorrhages occurred at INRs < 3.0. Even when adjusted for age, patients with subtherapeutic INRs (less than 2.0) were as likely as those with therapeutic INRs (2.0±3.0) to develop ICH (odds ratio = 1.1 [0.5±2.8]). CONCLUSION: The odds of ICH did not rise significantly until after age 85 and at INRs over 3.5. Concomitant aspirin plus warfarin use was not a significant risk factor. The lower INR ranges that some guidelines have recommended for elderly patients were not associated with a lower risk of ICH. Given that the risk of ischemic stroke rises sharply at INRs < 2.0, our study supports maintaining AF patients in the therapeutic anticoagulant range. BACKGROUND: Occupational exposure to hepatitis C virus (HCV) is a serious concern among people who work with HCV-infected populations, such as health care workers, emergency responders and prison workers. Prior studies have found that prison inmates have a high prevalence of HCV infection (34%), yet the prevalence and predictors of HCV infection among prison workers is not known. We investigated the prevalence and risk factors for HCV infection in a diverse sample of prison workers in California correctional institutions. METHODS: We conducted a cross-sectional study of workers in six California State correctional facilities and recruited subjects using two methods: (1) a proportional random sample of four occupational categories (guards, medical personnel, administrative, maintenance/housekeeping) using facility mailing, and (2) a volunteer sample recruited by site advertising. A total of 1,013 (819 randomly sampled and 194 volunteer sample) consented to participate in a structured interview assessing risk factors, including behavioral and occupational exposures, and HCV testing. Blood samples were assayed for HCV antibodies (anti-HCV) by EIA-3, and positive results confirmed by HCV-RIBA. In anti-HCV negative samples, HCV RNA was tested by a qualitative transcription mediated amplification (TMA) assay to detect recent seronegative infections. 77.9% of participants returned for results and post-test counseling. RESULTS: The prevalence of anti-HCV was 2.1% overall. No differences were found in HCV prevalence by sampling methods (random vs. volunteer), but volunteers were older (median 43 vs 47, p < 0.01). A high proportion (57.3%) of the overall sample reported ever having blood/bodily fluid exposures in the workplace (needle stick injuries, splashes with blood/body fluid, cuts with sharp objects during job duties). Bivariate analyses revealed that job category, duration of time working in prisons and occupational injuries were not associated with anti-HCV. All 21 seropositive workers had identifiable risk factors other than occupational history. In multivariate analyses controlling for age, exposures independently associated with anti-HCV were history of injection drug use (OR 88.3, 95% CI 27.3±286.1) and history of tattooing/body piercing (OR 4.4, 95% CI 1.2-16.4). CONCLUSION: We found a prevalence of anti-HCV among prison workers (2.1%) that was similar to the prevalence in the U.S. general population (1.8%). These findings suggest that workers in California prisons have a very low risk of acquiring HCV via occupational exposures and are consistent with the low prevalence of HCV among health care and dental workers. Efforts towards education and infection control will help to both minimize the possible spread of HCV in the prison setting as well as alleviate some of the concern among workers. BACKGROUND: Metabolic syndrome affects over 20% of the US population. The syndrome is defined as ! ! ! !3: abdominal obesity; elevated serum triglycerides or blood pressure; low high density lipoprotein (HDL) cholesterol, or high fasting serum glucose. We examined each criterion and the combination of these criteria in the metabolic syndrome to determine if gender and racial differences existed. METHODS: We analyzed data on 8,813 adult men and women from the Third National Health and Nutrition Examination Survey (1988±1994), a cross sectional health survey of a nationally representative sample of the US population. All subjects fasted ! ! ! ! 8 hours completed a health survey and a physical and laboratory exam. Subjects were diagnosed with the metabolic syndrome if they had ! ! ! !3: abdominal waist circumference (OBESE) >102 cm in men, 88cm in women; serum triglycerides (TG) ! ! ! !150 mg/dL, serum HDL cholesterol < 40 mg/dL in men, <50mg/dL in women; blood pressure (HTN) ! ! ! !130/85 mmHg or taking HTN medication; or fasting serum glucose (FBS) ! ! ! !110 mg/dL or taking anti-diabetic medication. We stratified the 5 criteria by gender and 3 racial groups and analyzed the 16 possible patterns. The percentages of the criteria in the patterns were calculated to determine their contribution to the diagnosis of the metabolic syndrome within each racial and gender group. Analyses were performed using SUDAAN and were weighted to reflect national estimates. RESULTS: There were 1,227 women and 973 men in the sample who met criteria for metabolic syndrome. For all women, OBESE was the most common criterion (Mexican Americans (97.2%), Blacks (95.8%), and Whites (92.7%). If OBESE was removed from the criteria, only 55% of women would have qualified for the metabolic syndrome. OBESE in men, however, was only present in 71.9% of Mexican Americans, 74.9% in Blacks, and 79.4% in Whites. For men, HTN was the most common criterion in Blacks (84.0%) while TG was in Mexican Americans (83.5%) and Whites (82.6%). For women, most common pattern in Mexican Americans and Whites was OBESE, low HDL, and TG (32.7%, 21.6% respectively), while for Blacks it was OBESE, low HDL, and HTN (26.9%). For men, the most common pattern in Mexican Americans was OBESE, low HDL, and TG (20%), while for Whites it was all criteria except FBS (19.4%). In Blacks it was OBESE, TG, and HTN (14%). CONCLUSION: Central obesity is the major criterion of the metabolic syndrome in women. Characteristics and patterns of the metabolic syndrome vary depending upon gender and race. BACKGROUND: Low back pain (LBP) is the second most common reason for medical care visits in Japan, yet its prevalence, burden, and associated factors have never been examined in Japan. This study's objective is to estimate the prevalence of LBP in Japan, to measure its burden on patients and on society, and to identify the psychosocial factors associated with LBP-related outcomes. METHODS: We surveyed a random sample of 4500 Japanese individuals, stratified by city size of residence and region to match the population distribution of the 2000 national census. Each of 300 sampling locations in the 43 strata contributed 15 respondents each. The selfadministered questionnaire includes items measuring LBP-related outcomes, including quality of life (QOL), missed work, and use of the health care system. Psychosocial variables were measured with the 14-item Job Content Questionnaire ( JCQ), the 20-item Perceived Stress Social Questionnaire (PSS), and a 2-item job satisfaction scale. Multivariate analyses were conducted to identify associations between factors and outcomes. All analyses were adjusted for age, sex, and comorbidities. RESULTS: The response rate was 66%. The overall prevalence of LBP was estimated to be 30%, and the prevalence increased with age. As measured with the SF-36, QOL for respondents with LBP was significantly lower than the population-norm, not only in the physical domains (À0.4 to À1.0SD, P < .01) but also in the mental domains (À0.4 to À0.5SD, P < .01). Of 845 respondents with LBP, 102 (11%) reported missing work a mean of 1.2 days of work, and 281 (32%) made an average of 2.4 outpatient clinic visits. Higher PSS scores and lower job satisfaction scores were significantly associated with missing work (P = 0.02, 0.03) and visiting an outpatient clinic (P = 0.03, 0.04), independently of the severity of pain. CONCLUSION: Low back pain has a substantial burden in Japan, both at the individual and societal levels, and is associated with psychosocial factors amenable to intervention. The high prevalence, personal implications, and demands on health care associated with LBP indicates the importance of primary care physicians in educating the public about recognizing and preventing LBP, as well as in treating it. BACKGROUND: Low back pain (LBP) is the second most common reason for medical care visits in Japan, yet how patients seek care for LBP has never been examined. Knowing these care-seeking patterns would allow primary care physicians to intervene more effectively in this population. This study's objective is to identify how people with LBP seek medical care.
NO INCREASED RISK OF HEPATITIS C VIRUS
RACIAL AND GENDER DIFFERENCES IN CHARACTERISTICS AND PATTERNS OF
THE PREVALENCE AND BURDEN OF LOW BACK PAIN
CARE-SEEKING BEHAVIOR FOR LOW BACK PAIN
METHODS:
We surveyed a random sample of 4,500 Japanese individuals stratified by city size of residence and region to match the population distribution of the 2000 national census. Each of 300 sampling locations in the 43 strata contributed 15 respondents each. The selfadministered questionnaire included items measuring LBP-related outcomes, including the use of the health care system and missed work. A clinical prediction rule verified from the previous study data distinguished people with a high probability of radiculopathy (HPR) from those with a low probability (LPR). We compared these two groups' care-seeking behaviors. Multivariate analyses were adjusted for age, sex, and comorbidities. RESULTS: Among 865 respondents with LBP (estimated prevalence; 30%), 28% was classifiend into a HPR. Of these, 63% made no outpatient visits, a proportion similar to those with LPR (66%) (P = 0.41). Furthermore, the HPR group sought alternative medical care as frequently as did the LPR group (chiropractic 50%, massage therapy 29%, acupuncture 23%, Shiatsu 15%), with or without visits to orthopedic surgeons (56.5%) and primary care physicians (9.6%). Significantly more HPR (16.7%) missed their work than LPR (11.7%), after adjustment for age, sex and comorbidity. (P = 0.04). CONCLUSION: People with LBP, even those with higher clinical severity, do not often seek primary care for their pain but are much more likely to seek specialty care or alternative medical care, while reporting higher work-productivity loss than those with less severity. Primary care physicians need to be more active in educating the public on prevention, assessment, and treatment of LBP. BACKGROUND: While infection with HIV or hepatitis C virus (HCV) is known to be associated with increased symptom burden, there is little literature examining symptom burden and its effect on quality of life (QOL) in coinfected patients. METHODS: The Veterans Aging Cohort 3-site Study is a longitudinal study of 881 HIV+ veterans at 3 sites. The baseline survey measured QOL using Short-Form 12 (SF-12) and measured symptoms based on the ACTG symptom index which inquires about the presence of 20 symptoms over the previous four weeks, and if present how bothersome each symptom was. HCV antibody and baseline aminotransferase levels (``LFTs'') were also collected, with elevated LFTs defined as levels >1.5Â upper limit of normal. Patients were categorized as (1) HCV-(n = 400), (2) HCV+, normal LFTs (n = 87), and (3) HCV+, elevated LFTs (n = 213). We used linear regression to determine the proportion of variation in QOL explained by symptoms. Nonparametric test of trend was used to determine whether symptom burden increased across the three groups. RESULTS: Symptom burden increased across the groups (Table) . For 12 of the 20 (60%) symptoms bothersome increased (p < 0.05) and trended towards increasing in one (p <= 0.1). Symptoms explained 27% of variation in physical component score and 42% of variation in the mental component score. Viral load and CD4 count did not differ. CONCLUSION: Hepatitis C coinfection was significantly associated with increasing symptom burden and was associated with increasing bothersome of the majority of the symptoms measured in the VACS 3 study. Patients with hepatitis C infection but normal LFTs had a larger bothersome symptom burden than hepatitis C negative patients; while hepatitis C positive patients with elevated LFTs had the largest burden. This study suggests that additional research into the management of symptoms in HIV/HCV coinfected patients has the potential of increasing patients' QOL. BACKGROUND: Chronic pain effects a large proportion of our patient population. Unbeknownst to their physicians, patients might be using other remedies to treat their illnesses in addition or instead of conventional therapies. The objective of our study was to determine prevalence of complementary alternative medicine (CAM) use in patients with nonmalignant chronic pain and to identify patient characteristics associated with CAM use. METHODS: The 4P (Patient-Physician Perception of Pain) study group is a multi-center collaboration formed to assess patient and physician attitudes regarding primary care management of non-malignant chronic pain using a cross-sectional study design. This arm of the study involved a 160-item survey administered to 346 patients who suffered from nonmalignant chronic pain. Sections of the survey consisted of demographic questions, attitudes toward care, and use of conventional and CAM therapies. We analyzed the descriptive data on the use of CAM in addition to bivariate and multivariate analyses in order to identify patient characteristics associated with CAM use. In a logistic regression model, we controlled for: age, education level, pain duration, narcotic use, race, gender, depression, and patient satisfaction with health care provided. RESULTS: Fifty-six percent (194) of patients used CAM such as cod liver oil (4%), acupuncture (2%), massage (17%), garlic (11%), primrose oil (2%), chiropractor (9%), meditation/yoga (7%), traditional Chinese medicine (1%), aromatherapy (5%), vitamin/ mineral supplements (37%), and others (8%). Of the patients surveyed, sixty-eight percent were women, 46% were whites, 32% had an education level greater than high school. Fiftynine percent used narcotics, 37% of the patients were depressed, and 83% reported good to excellent satisfaction with the health care provided. Bivariate analysis revealed that 65% of the patients with an education level higher than high school used CAM compared to 52% of the patients with a lower education level (p = .02). In the logistic regression, an education level higher than high school continued to be associated with CAM use (odds ratio [OR] BACKGROUND: Diabetes is a growing problem in America. The American Diabetes Association recommends interventions for patients with an A1C greater than 8%. Current surveillance protocols recommend A1C testing every 3 to 6 months. To our knowledge, no patient cohorts have been studied to determine the risk of reaching the action threshold from an initial A1C. METHODS: We used a lab registry of all A1Cs between 1998 and 2001 processed at one academic medical center to select cases. We excluded patients under the age of 40 and patients with a history of amputation, dialysis, or kidney transplant. We only included patients with at least one additional recorded A1C values within 360 days of the initial A1C. We restricted our analysis to patients with an initial A1C greater than 6.0% and less than 8.0%. We used cumulative hazard functions to determine time-to-A1C of 8.0% or greater. RESULTS: 1872 patients met our selection criteria. We found no differences by gender or age quartiles (data not shown). We found significant differences when grouping initial A1C into 0.5% increments. BACKGROUND: Evidence-based treatment of diabetes generally requires multiple medicines to control metabolic risk factors. We assessed medication adherence and predictors of suboptimal adherence in patients with diabetes and tested the hypothesis that adherence decreases with increased number of medicines prescribed. METHODS: One-hundred and twenty-eight randomly selected patients with type 2 diabetes from a single community health center responded to a pharmacist-administered questionnaire regarding medication use. Survey data were linked to clinical data available from the electronic medical record. We assessed self-reported adherence rates for each diabetes-related medicine, barriers and attitudes regarding medication use, and last measured hemoglobin A1c, total cholesterol, and blood pressure. RESULTS: Patients were taking a mean of 4.1 (1.9) diabetes-related medicines. Average 7-day adherence was 6.7 1.1 days. Total number of medicines prescribed was not correlated with medication adherence. Adherence was significantly lower for medicines not felt to be improving current or future health (6.1 vs. 6.9 days out of 7, p < 0.001). Among patients on 3 or more medicines, 71% (15 of 21 patients) with sub-optimal adherence were perfectly adherent with all but one medicine. Side effects were the most commonly reported problem with medication use. Of 29 medicines causing side effects that interfered with adherence, 24 (83%) did so for greater than 1 month and only 7 (24%) were reported to the patient's primary care physician. CONCLUSION: In this sample, patients reported very high medication adherence rates regardless of number of medicines prescribed. Among patients on multiple medicines, most patients with sub-optimal adherence had decreased adherence to only one medicine. Unreported side effects and a lack of confidence in immediate or future benefits were significant predictors of sub-optimal adherence. BACKGROUND: Asthma morbidity and mortality is highest among inner-city populations. The aim of this study was to assess the extent to which disparities in asthma may be influenced by suboptimal self-regulation beliefs, behaviors, and participatory decision making (PDM) in a cohort of inner city adults with moderate and severe persistent asthma. METHODS: A prospective cohort of adults admitted to an urban hospital over a consecutive 12 month period were interviewed to assess self-management knowledge, beliefs, and behaviors (medication use, peak flow [PF] use), and 5 items adapted from a validated PDM scale. ED visits and hospitalizations for asthma in the past year were assessed on admit and 1 month after discharge (86% follow-up); 28% of interviews were in Spanish. RESULTS: Overall, 204 eligible Pts (96%) were enrolled. Mean age was 49.8 yrs (range 19±101), 78% were female, 62% were Hispanic, 28% African-American, and 5% White. The mean asthma ED visits and hospitalizations in the yr prior to admission were 3.4 5.2 and 1.4 2.6. One month after discharge, 19% had an ED visit and 10% were readmitted for asthma. While 92% of Pts had insurance and 82% a usual place of asthma care, 66% reported ever being prescribed inhaled corticosteroids (ICS). Among these, 73% used them daily when they had symptoms (SX) and 58% took them daily when no SX (p < .05). While 79% had a PF meter, and 85% said it was easy to use, only 27% used it, and 71% never used PF to adjust medicines. Among the PDM items, 40% made asthma decisions together with their MD, and 49% said their MD asked them to take some responsibility for their own care; 69% said their MD never discussed how to adjust their medicines themselves, and 62% never discussed SX or PF goals, though 74% would tell their MD if a medicine was not helping. The mean PDM score was 3. Standard meta-analytic methods were used, including sensitivity analysis, assessment of heterogeneity, and publication bias. RESULTS: Twenty-two studies were identified: 8 evaluating statin effects in men and women, 14 exclusively women. 16 were observational studies and 6 randomized controlled trials; 3 RCTS were secondary analysis of cholesterol lowering trial data, and the remaining RCTs assessed statin effects on BMD or bone markers. Among studies including both men and women, statin use was associated with fewer hip fractures (OR: 0.61, 95% CI: 0.5±0.75) and improved hip BMD (SMD: 0.12, 95% CI: 0.06±0.17), with no effect on vertebral fracture or BMD. Among studies focusing on women, hip BMD improved (SMD: 0.10, 95% CI: 0.04± 0.16), with a nonsignificant reduction in hip fractures (OR: 0.78, 95% CI: 0.52±1.16), though a reduction in overall fracture rates was seen (OR: 0.82, 95% CI: 0.75±0.89). Markers of bone turnover, alkaline phosphatase, osteocalcin, and C-telopeptide all improved (SMD: À0.28, 95% CI: À0.40 to À0.16; SMD: À0.33 95% CI: À0.53 to À0.14; SMD: À0.17, 95% CI: À0.31 to À0.1, respectively). CONCLUSION: HMG-CoA reductase inhibitors may have a beneficial impact on bone metabolism, bone density, and decreased fracture risk in men and women. BACKGROUND: Hypoglycemia is an important complication of insulin treatment. We evaluated the incidence, severity, and predisposing factors for hypoglycemic episodes in insulin-treated patients with type 2 diabetes. METHODS: We conducted a prospective observational study of Southwest veterans with stable, insulin-treated type 2 diabetes. Subjects were randomly selected from pharmacy databases. Electronically-recorded self-monitored blood glucose (SMBG) results were collected during 12 months of routine monitoring. We defined hypoglycemia as an SMBG reading <= 60 mg/dL. Subjects graded the severity of each hypoglycemic episode (0 = asymptomatic, 1 = mild/moderate symptoms, 2 = severe, with mental impairment or need for assistance. Subjects also reported any predisposing factors for each hypoglycemic episode. RESULTS: We enrolled 344 subjects, mean (SD) age was 65.5 (9.7) years, 96.5% were men, and 35.3% were Hispanic or African American. During a mean (SD) follow-up of 41.2 (8.6) weeks, 176 subjects (51.2%) documented at least one hypoglycemic reading, with a total of 1,662 episodes. Among subjects who became hypoglycemic, the median number of episodes was 4, occurring at a rate of 0.91 episodes/4 weeks. The mean (SD) hypoglycemic blood glucose reading was 49.7 (7.5) mg/dL and the mean (SD) symptom score was 0.84 (0.45). Nearly 20% of episodes were asymptomatic, but 3.4% were severe. Subjects recorded comments for 97% of the hypoglycemic episodes. Although subjects could not identify a cause for 51.6% of the episodes, 24.1% were attributed to missing a meal, 10.8% to exercise, and only 0.7% were attributed to a medication increase. CONCLUSION: A high proportion of stable, insulin-treated subjects developed hypoglycemic episodes, but severe hypoglycemia occurred infrequently. Hypoglycemic episodes were rarely attributed to medication increases. Efforts to achieve tight glycemic control should recognize that patient behaviors are the most common cause for hypoglycemia. BACKGROUND: Metabolic syndrome (MS) is a constellation of metabolic disturbances including insulin resistance, glucose intolerance, elevated blood pressure (BP), dyslipidemia (DLP), and central obesity (OB). Patients with MS are at increased risk of developing diabetes mellitus (DM) and coronary artery disease (CAD) and increased mortality from all causes including CAD. Although OB and DM disproportionately affect minorities and those served in public hospitals, the prevalence of MS in this vulnerable population has not been assessed. The purpose of this study was to determine the prevalence of MS and its major disease components in a university-based public hospital. METHODS: A chart review was conducted on 928 patients seen in two primary care clinics between May and July of 2002. Height, weight, and waist circumference (WC) were measured with patients wearing one layer of light clothing and no shoes. Sitting blood pressure (BP) was obtained. Body mass index (BMI) was calculated as weight (kg)/height (m 2 ). Determinations of fasting blood glucose (FG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) were retrieved from a hospital computer database. MS was defined as >/= three of the five diagnostic criteria as outlined in the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII). Student's t test and Chi-square test were used for the analyses of continuous and categorical variables, respectively. RESULTS: Seventy percent of patients were black, 68% were female, and 4% were commercially insured. Mean patient age was 53 years; BMI 31 kg/m 2 ; WC 99 cm; BP 139/ 75 mmHg; FG 120 mg/dl; TG 178 mg/dl; and HDL-C 48 mg/dl. The prevalence of MS was 52%, OB 53%, HTN 70%, DM 29%, DLP 36%, and CAD 15%. Fifty-six percent of patients with MS met at least 4 diagnostic criteria. Women had a higher prevalence of MS than men (P < 0.05) with the highest prevalence in black females (P < 0.01). Patients with MS were older and had higher values of WC, FG, BP, and TG, and lower values of HDL-C (P < 0.0001). Patients with MS were more likely to have a diagnosis of OB, HTN, DM2, DLP, or CAD (P < 0.0001) and were more likely to have atherogenic DLP characterized by high TG and low HDL-C than patients without MS (p < 0.001).
HEPATITIS C COINFECTION IS ASSOCIATED
IMPACT OF CONCURRENT MEDICATION USE ON STATIN ADHERENCE AMONG PATIENTS ENROLLED IN
CONCLUSION: The prevalence of MS in this public hospital is higher than National data suggest. Patients with MS have significantly more co-existing OB, HTN, DM2, atherogenic DLP, and CAD than those without MS. Routine measurement of WC during clinic visits is practical and may be useful for early identification of MS. BACKGROUND: We examined the degree to which NSAID exposure is associated with hospitalizations for peptic ulcer disease (PUD) in Argentina. METHODS: A retrospective case-control study was conducted by reviewing medical records of patients admitted with PUD at one of five hospitals between 1996 and 2002. Complicated PUD was defined as cases with hematemesis, melena, or GI hemorrhage. One control (admitted for reasons other than PUD) was identified for each case, matched by age, sex, and admission date. The McNemar and Wald tests were used, as appropriate, to test for differences in exposure among cases and controls. RESULTS: 371cases were identified. Mean age was 69 years and 46.5% were female. Based on the discharge diagnosis, 42.3% of the cases had a complicated PUD, 52.5% an uncomplicated PUD, and 5.2% had gastritis/duodenitis. At admission, 83.6% presented with a GI bleed, and 89.0% were admitted via the emergency room. During the one year prior to admission, 58.0% of cases vs. 28.3% of controls used NSAIDs and 41.0% vs. 18.9% used aspirin (both p < 0.05). Conditional logistic regression analysis, adjusting for age, use of gastroprotective agents, antacids, and aspirin during the last year, number of anti-rheumatic medications, and history of asthma, hyperlipidemia, renal disease, upper GI bleeding, and musculoskeletal disease revealed that the odds of a hospitalization for PUD was 4.7 times higher among patients using NSAIDs during the prior year than non-users (OR 4.7; 95% CI: 2.5±8.8). Subgroup analyses adjusted for the same covariates showed that prior NSAID use was significantly associated with both complicated PUD (OR 4.5; 95% CI: 1.8±11.3) and uncomplicated PUD (OR 5.8, 95% CI: 2.2±15.5). History of GI complications was an independent risk factor for complicated PUD (OR: 12.8) and uncomplicated PUD (OR: 31.3). Endoscopic tests were performed in 96.0% of cases vs. 0.9% of controls, and red blood cell transfusions in 56.0% vs. 6.1% (all p < 0.05). On average, cases were hospitalized for 5.2 days (SD: 5.8) and this was not significantly different from controls. 52.3% of cases were treated in the ICU, 6.2% had an upper GI surgery performed, 25.4% had a Helicobacter pylori test taken and 2.4% a urea test during the hospitalization. CONCLUSION: Use of NSAIDs is an independent risk factor for both complicated and uncomplicated PUD patients in Argentina. BACKGROUND: Hypertension (HTN), dyslipidemia (DL), and diabetes (DM) are risk factors for cardiovascular (CV) disease. The purpose of this study is to estimate the prevalence of concurrent HTN, DL and DM among patients in the VA. METHODS: Computerized records for 69,558 patients from the Houston VA Medical Center were collected for October 1998 to September 2001. Patients were classified into mutually exclusive cohorts based upon the presence of HTN, DL or DM. We defined disease based on diagnostic, treatment, and clinical parameters using recent ATP III, ADA and JNC VI guidelines. The demographic profile and pre-existing CV comorbidities including myocardial infarction (MI), angina or coronary artery disease (CAD), peripheral arterial disease (PAD) and cerebrovascular disease (CEVD) were determined for each cohort. RESULTS: The table below shows the overall age, sex, race, and CV comorbidities for patients in each cohort. 51,028 patients (73.4%) had HTN, DL or DM. The prevalence of each condition alone was 24.3%, 5.1% and 1.3%, respectively. 16,355 patients (23.5%) had HTN and DL, and 9,632 patients (13.9%) had all three conditions. The average age was 60.7 years and 96% were male. Fifty-three percent of the patients were White, 25.3% Black, and 5.6% Hispanic. 6.2% had history of MI, 32.1% CAD, 7.7% PAD and 10.5% CEVD. The prevalence of preexisting CV comorbidities were dramatically higher for patients with concurrent conditions. CONCLUSION: The prevalence of various combinations of concurrent HTN/DL/DM was very high in this population of predominately male, U.S. veterans. Patients with concurrent disease were more likely to have other CV comorbidities. Primary care physicians need to be aware of the mulitiple conditions for the most effective management of these patients. BACKGROUND: The purpose of this study is to describe treatment patterns and attainment of treatment goals for hypertension (HTN), dyslipidemia (DL), and diabetes (DM) among patients in the VA health care system.METHODS: Computerized patient records for 69,558 patients from the Houston VA Medical Center were collected for the period October 1998 to September 2001. Patients were identified using diagnostic, treatment and clinical parameters and were classified into inception cohorts of newly diagnosed and treated patients with isolated or concurrent HTN, DL or DM. The frequency of utilizing distinct classes of medication therapy was determined. All patients were tracked in the database for at least one year. Goal attainment based on JNC-VI, NCEP, and ADA guidelines was determined at the end of the study period. RESULTS: There were a total of 9,509 patients identified in the inception cohorts. Over half of these (n = 5,482 or 57.2%) had isolated HTN. Rates of no treatment ranged from 31.6% to 62% for patients with isolated conditions. Rates of multiple drug class use ranged from 1.5% to 20.2% in patients with isolated conditions, but from 2.2% to 54.9% in patients with more than one condition. Average length of followup was 1.75 years. Goal attainment in patients with HTN alone was about 45%, but decreased to 27% in patients with HTN, DL, and DM. For patients with DL or DM, goal attainment was highest if they had all three conditions, rather than in isolation. CONCLUSION: Based upon the utilization of drugs and multiple therapeutic classes, physicians appear to be treating patients with multiple conditions more aggressively, which may reflect these patient's increased risk for coronary heart disease. However, less than 50% of patients reached therapeutic goals for any condition. Further research is needed to examine determinants of patient adherence and physician practice patterns to improve outcomes. BACKGROUND: Elevated C-reactive protein (CRP), a marker of systemic inflammation, has been associated with prediction of future coronary disease (CAD), stroke and recently with persistence of atrial fibrillation (AF). We tested the hypothesis that in patients who have manifest CAD, higher inflammatory burden, as marked by elevated CRP, is associated with AF. METHODS: Patients undergoing percutaneous coronary intervention (PCI) had baseline ECGs and CRP levels assayed. Patients in AF prior to PCI were compared to those in sinus rhythm. Data were analyzed using t-or Wilcoxon rank-sum tests. RESULTS: Of 1335 patients, 38 (2.8%) were in AF on baseline ECG. Unstable angina (UA) or acute myocardial infarction within 30 days (AMI) was present in 23 (60.5%) AF pts and in 820 (63.4%) non-AF pts, p = ns. AF patients had significantly higher CRP levels than non-AF patients (3.04 4.86 vs 1.52 2.96 mg/dl, p = 0.002). Other univariate predictors of higher CRP included UA (1.67 3.04 vs 1.172.58 mg/dl, p < 0.001), AMI (3.59 5.02 vs 1.7 2.05 mg/ dl, p < 0.001) and decreased LVEF (r = À0.190, p<0.001). Multivariate analysis showed that AF, AMI, LVEF, COPD, and renal failure were independent predictors of higher CRP (Table) . CONCLUSION: In patients with CAD undergoing PCI, AF was associated with higher CRP. This association remained significant after controlling for other comorbidities. These data further support a potential role for inflammation in the pathophysiology of AF. BACKGROUND: Chronic pain is often under-treated by clinicians in the primary care setting. One measure of successful pain management is patient satisfaction. Our study examines factors that influence a chronic pain patient's degree of satisfaction with their primary care provider. METHODS: The 4P study (Patient and Physician Perception of Pain) is a multi-center, cross sectional study of patients' and their physicians' attitudes and preferences regarding chronic pain care. A survey was administered to patients with 3 months or more of chronic, non-cancer pain just prior to their doctor's appointment, and a follow-up phone interview was conducted 2 weeks later. Our main outcome was patient satisfaction at the 2-week follow-up. We performed bivariate analysis examining factors associated with patient satisfaction and then combined these factors in a logistic regression model controlling for potentially confounding variables such as race, gender, severity of pain, depression, narcotic use, continuity of care, and discordance between patient and physician in rating the patient's level of pain severity. RESULTS: We report preliminary data based on the first 346 patients surveyed: 70% were female, 76% were insured, and 33% said they were depressed. Discordance between patient and physician of 2 or more points on the 10-point pain scale occurred in 46% of office visits. Of 234 completing the 2-week follow-up so far, 153 (66%) indicated they were satisfied with their care. Of those patients who said their MD educated them about their pain, 73% reported they were satisfied with their care compared to only 25% satisfaction in those who reported not being educated (p = .001). Age, gender, race, pain severity, discordance and depression were not associated with patient satisfaction. After combining education with these variables in the logistic regression model, we found that educating the patient about their pain remained the only significant factor associated with patient satisfaction, OR 3.2(95% CI 1.4, 7.0). CONCLUSION: Patient education about chronic pain is associated with better patient satisfaction in the primary care office setting. Surprisingly, patient satisfaction is not associated with discordance or pain severity. Further study should investigate what specific educational content leads to improved patient satisfaction and whether satisfaction results in better outcomes. BACKGROUND: We described and compared symptom distress and quality of life among persons receiving hospice/palliative care from the perspective of patients and proxies (caregivers and nurses). We hypothesized that 1) proxy respondents would rate symptom (sx) distress higher and quality of life (QOL) lower than would patients, 2) patient and nurse assessments would be highly correlated, and 3) correlations would be higher for physical than for psychological issues. BACKGROUND: Readmission for congestive heart failure (CHF) after hospital discharge represents a significant burden to the patient and the health system. METHODS: 151 adults hospitalized for CHF were enrolled in a prospective, randomized, controlled study of a nurse-administered, telephone-based disease management program. Outcomes included hospital readmission, mortality, functional status, and satisfaction with care. The intervention included scheduled telephone calls by specially trained nurses. The nurses promoted patient self-management, provided dietary counseling, and encouraged adherence to guideline-based therapy prescribed by primary physicians. The nurses also screened for increased heart failure symptoms. When there was evidence of exacerbation, supplemental (``rescue'') diuretics were administered, or the primary physician was contacted for instructions. Patients were called within 3 days of discharge and then at least weekly for 2 weeks. Call frequency then varied based on the patient's clinical status and self-management abilities. Control subjects received no post-enrollment contact. RESULTS: The mean age was 70 years. 56% of the subjects were female. 57% were AfricanAmerican. 80% were NYHA class III or IV. 87% had at least one additional serious co-morbid illness. 91% were retired, disabled, or unemployed. The control and intervention groups were well matched with regard to demographics, left ventricular function, NYHA classification, and comorbidity. Over 1 year, intervention patients had a longer time to encounter (hospital or emergency room visit) than control patients (HR = 0.67; 95% CI 0.47±0.96; P = .029). They also had longer time to hospital readmission (HR = 0.67; CI 0.46±0.99; P = .045) and CHFspecific readmission (HR = 0.62; CI 0.38±1.02; P = .062). Cox proportional hazard analysis controlling for ejection fraction, NYHA class, and comorbidity yielded little change. For example, for time to encounter, HR = 0.60 (CI 0.35±1.02, P = 0.062). Intervention and control patients did not differ with respect to survival, functioning, or satisfaction with care. CONCLUSION: A nurse-administered, telephone-based disease management program including frequent monitoring, judicious use of supplemental diuretics, and patient education significantly delayed subsequent healthcare encounters. The program had minimal impact on functional status, satisfaction, or mortality. We analyzed data from a prospective, placebo-controlled trial of pred with or without methotrexate (MTX) in GCA for pred induced HTN. All GCA patients (creat <2.0) enrolled in this trial received pred 1 mg/kg/day. BP was to be measured at all visits. The primary end point of our retrospective analysis of the data was BP change from the baseline, measured at 2 weeks following initiation of pred. RESULTS: Data from 44/89 of the patients enrolled in the initial study were evaluable in this analysis of HTN following pred. therapy. Patients who had manipulation of anti-hypertensive medications because of BP elevation (independent of steroid effect) between 0 and 2 weeks (n = 2) and those in whom pred was started prior to initial visit form completion (n = 39), or were missing BP data at 2 and 4 weeks (n = 4) were excluded from this analysis. Pts. were evaluable if baseline and either 2 or 4 week BP were recorded. BP at the scheduled 2 and 4-week visit following start of pred. therapy was compared to the pre-pred BP; difference was evaluated for each patient. There was 99% power to detect a difference of 10mm with a sample size of 33.There was no statistically significant difference between the group mean syst or diast BP at 2 (p values of 0.96 and 0.63, n = 42) or at 4 weeks (p values 0.58 and 0.82, n = 33) when compared to baseline. But the # of patients with >5 mm Hg increase in SBP at 2 weeks was 19 (44%) and at 4 weeks was14 (42%); in DBP was 18 (42%) at 2 weeks and 11 (33%) at 4 weeks. # Pts who had >10 mm Hg SBP increase at 2 weeks was 12 (28%) and at 4 weeks was 7 (21%); 10 (23%) had >10 mm inc DBP at 2 weeks and 9 (27%) at 4 weeks. SBP and DBP increase at 2 weeks was more common in patients who had baseline HTN, at 4 weeks this relationship was only seen with DBP. CONCLUSION: Although pred therapy did not cause a change in the group mean diastolic or systolic BP, it did cause > 10mm elevation in systolic or diastolic BP in $25% of patients with GCA, median age 74 (55±89). It is therefore important to closely monitor BP in older patients who are started on high dose prednisone at 2 weeks after start of therapy, especially in patients who have a history of baseline hypertension.
NSAID EXPOSURE AMONG PATIENTS HOSPITALIZED FOR COMPLICATED AND
TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH
ATRIAL FIBRILLATION IS ASSOCIATED WITH ELEVATED C-REACTIVE PROTEIN IN
SYMPTOM DISTRESS AND QUALITY OF LIFE AT THE END OF LIFE
DIABETES DOCUMENTATION DURING PREGNANCY
METABOLIC SYNDROME-DEFINING FACTORS AND PROSTATE CANCER MORTALITY. BACKGROUND: Most prostate cancer (CaP) occurs in older men. These patients often have various chronic illnesses before cancer detection. It is possible that such comorbidity may actually modify the biology and outcome of CaP. Westernization is associated with an increased incidence of clinically significant CaP as well as Syndrome``X'' (SX) or thè`m etabolic syndrome''. SX is defined by central obesity, insulin resistance, hypertension, dyslipidemia, atherosclerosis, and hyperuricemia. One study has shown an association between SX and colorectal cancer mortality. We speculate that the presence of this syndrome may be associated with more lethal CaP. Specifically, we hypothesize that men who die of metastatic CaP, in comparison with men of the same age but without evidence of symptomatic CaP, are more likely to have SX-defining factors. METHODS: This is a case-control study with frequency matching for age, race, and the time available for diagnosing SX factors. Cases are men (ages 55±70) who died from metastatic CaP from 1997 to 2000. They were sampled from a population-based cancer registry. Controls were sampled from the same population from which cases arose. Time available to have SX factors diagnosed was nearly identical for both groups. Only factors diagnosed before the case diagnosis of CaP were counted to reduce observation bias. The number of factors present in each subject were used to create an index (0±6). The chi-square test for categorical variables and Student's t-test for continuous variables were used in bivariate analysis. Multivariable logistic regression was used for modeling the outcome as a function of the number of metabolic risk factors present controlling for potential confounders (age, socioeconomic status, and race). RESULTS: Two thirds of cases and one half of controls had one or more SX factors diagnosed. The following SX factors were significantly associated with CaP mortality: hypertension (OR = 2.2 95%CI 1.46, 3.4), atherosclerosis (OR = 1.8 95%CI 1.1, 2.8), insulin resistance (OR = 2.1 95%1.1, 4.1), and abdominal obesity (OR = 1.7 95%CI 1.05, 2.7). In multivariable logistic regression analysis with adjustment for age, race, and education, hypertension and atherosclerosis retained their significance with ORs of 1.9 and 1.8 respectively. The model including the index variable for the number of component SX factors revealed a graded response with ORs ranging from 2.0 for one factor, 2.8 for 2±3 factors, and 3.4 for four factors (no SX factors as referent). All ORs for index categories were statistically significant with a lower 95% CI greater than 1.0. CONCLUSION: Metabolic syndrome-defining conditions appear to be risk factors for CaP mortality, and the level of this risk is graded in direct proportion to the number of component factors present in an individual. BACKGROUND: We studied associations between blood markers and the ankle brachial index (ABI) in patients with and without clinically evident coronary or cerebrovascular disease. METHODS: Participants were 601 patients with and without peripheral arterial disease (PAD). We measured d-dimer, prothrombin 1.2, high-sensitivity C-reactive protein (CRP), fibrinogen, and serum amyloid A (SAA). Presence of cardiac or cerebrovascular disease was determined by combining data from medical record review, a primary care physician questionnaire, and patient report. RESULTS: The table shows relationships between blood factors and the ABI among patients without known cardiac or cerebrovascular disease. In patients with cardiac or cerebrovascular disease, ABI was associated with d-dimer (p < 0.001) but not other blood factors. In multivariable regression analyses of all participants adjusting for all blood factors, comorbid disease, and other confounders, only d-dimer was associated independently with ABI (p < 0.001). CONCLUSION: D-dimer, a measure of ongoing thrombosis and fibrinolysis, may be more sensitive than other blood markers to atherosclerosis severity in leg arteries. BACKGROUND: To report antiretroviral (ARV) adherence rates in a multicenter cohort and to evaluate factors associated with``short-term'' (last 4 days) and``long-term'' (last 6 months) adherence to ARV therapy in patients with HIV/AIDS. METHODS: Self-reported adherence was assessed using a modified AIDS Clinical Trials Group measure in a cohort of 379 subjects with HIV/AIDS from 4 clinical sites in 3 cities in 2002. Adherence was evaluated using 2 distinct cut-offs: 100% adherent for at least the last 6 months and at least 95% adherent for the last 4 days. Covariates assessed for associations with adherence were: standard demographic characteristics; clinical characteristics; injection drug use (IDU) history (ever vs. never used); alcohol use (drinks per month); religiosity/spirituality; health status; depressive symptoms; symptom index (number of symptoms and degree of bother); social support; self esteem; optimism; and risk attitude. Univariate analyses were performed using the chi-square test or simple logistic regression. Multivariable analyses (including covariates with p-values 0.25 in univariate analyses) were performed using logistic regression. RESULTS: 74% (281 of 379) of participants reported being on a stable ARV regimen for at least the last month. Of those patients, the mean (SD) age was 43.8 (8.6) and the mean CD4 cell count was 413 (286), 88% were male, 51% were white, 23% were veterans, 14% had remote IDU, and 2% had active IDU. 34% (95 of 281) reported not missing any ARV doses in the last 6 months, and 73% (198 of 273) reported at least 95% adherence in the last 4 days. 38% of women vs. 33% of men and 33% of whites vs. 35% of non-whites reported not missing any ARV doses in the past 6 months (p = NS). In other univariate analyses, none of the covariates were significantly associated with``long-term'' adherence and only age was significantly associated with``short-term'' adherence (mean age of those that were adherent was 44.4 vs. 42.0 for those that were not adherent). In multivariable analyses, not working and having greater social support were significantly associated (p < 0.05) with 100% adherence for at least the previous 6 months, and older age and a lower symptom index were significantly associated with at least 95% adherence in the past 4 days. CONCLUSION:``Long-term'' adherence was associated with not working and having greater social support, while``short-term'' adherence was associated with older age and having few symptoms. These results imply that interventions that promote better symptom management and increase social support may improve adherence to ARV therapy. Given the general lack of significant association of sociodemographic characteristics with adherence, physicians should take care not to be overly influenced by those characteristics when forming their recommendations for treatment. BACKGROUND: Patient's (pt) attitude/perceptions about ART may influence the success of both short-term and long-term therapeutic management strategies. METHODS: 304 pts participated in an observational study of adult HIV patients for whom a change in ART was being considered by their providers. Pts completed a questionnaire (Qr) that obtained information on demographics, HIV risk behaviors, pt worries, pt-provider communication (about anti-HIV medicines), trust, and knowledge of actual CD4 & viral load (VL) counts. Pts were also asked about their attitude/perception about ART and its effect on: making them live longer (Q1), providing ability to fight off HIV/AIDS infection (Q2), improvement of HIV viral load (Q3) and CD4 count (Q4). Each of these 4 Questions were scored on a 5-point Likert scale (1:`definitely no'; 5:`definitely yes'). The 4 questions were combined to a composite score of 0 (worse attitude) to 100 (better attitude). Factors associated with patient's better attitude/perception towards ART were ascertained through a linear regression model with the following variables: pt demographics, risk behaviors, depression, medication (med) experience, pt-provider communication/trust, worries, and pt knowledge of their CD4/VL counts. RESULTS: Results: Pt demographics for 304 pts include: mean age 41 yrs; 31% female; 51% African American, 26% Hispan-ics, 17% Caucasians; 38% had AIDS; 33% had less than high school education; 67% had income below $15,000. 57% reported signs of depression & 32% reported substance abuse in the past yr. In response to the questions on attitude/perceptions towards ART, 54%, 65%, 64% and 66% answered`definitely yes' for Q1 through Q4 respectively. The mean composite score was 86.5. Pts with less than high school education had lower score compared to those educated at high school level or more (83.3 vs 88.2; p = .03); Pts with depression had lower scores compared to those without depression (84.9 vs 89.2; p = .05). In the linear regression model, lower pt-provider communication (p =< .01), lack of pt knowledge of CD4 and/or VL counts (p =< .01) and higher med worries (p = .02) were found to be associated with lower attitude/perception about ART. CONCLUSION: Our results suggest that the level of communication between pt-provider about anti-HIV meds, pt knowledge of their CD4 and/or VL counts and medication worries are important factors influencing pt attitude/perception about ART. BACKGROUND: Limited information is available on the impact of patient's HIV knowledge on their worries, general health perception and medication adherence. METHODS: HIV$PRACTICE Cooperative is an observational study of adult HIV patients (pts). An 83-item questionnaire was administered to 304 pts for whom a change in ART was being considered by their providers. Data was captured on pt demographics, HIV risk behavior, health perception, HIV knowledge, attitudes, medication (med) and HIV related health worries, pt-provider communication/trust, and Med adherence (having missed at most one dose in past 3 days). This analysis focused on data of pt's HIV-related knowledge assessed through 3 questions: what are Anti-HIV meds?, what is CD4? & what is viral load? Patients were classified as having answered correctly all 3 questions (group A), answered correctly 1 or 2 of 3 questions (group B), or no correct answer for any of the questions (group C). Pt demographics, knowledge, risk behaviors, worries, attitudes, pt-provider communication/trust variables were used in the logistic regression model to evaluate factors associated with med adherence. RESULTS: Descriptive statistics are shown in the table below. In the logistic model to predict adherence, after adjusting for other parameters, pts with higher knowledge (Group A compared to B/C; OR: 2.53, p = .03), Male pts (OR: 2.62, p = .03) and pts with less med worries (OR = 1.05, p < .01) were found more likely to adhere to meds, while pts with annual income <$15000 (OR = 0.37, p = .04) were found less likely to adhere to meds. CONCLUSION: Our findings suggest that, better HIV-related knowledge, higher income, less medication worries and male gender were associated with better med adherence. ). Bivariate analyses were used to describe self-perception of weight, desire to loose weight and weight loss attempts by weight category. Multivariate logistic analyses were used to identify individual characteristics associated with obesity. RESULTS: Fifty three percent of US adults were overweight (31%) or obese (14% class 1; 5% class 2; 3% class 3). While 33% of overweight adults did not consider themselves overweight and 26% did not want to weigh less, 45% reported trying to loose weight in the past year. Almost all obese individuals (class 1, 2, and 3) considered themselves overweight (90%, 97%, and 98% respectively) and would like to weigh less (92%, 97% and 99% respectively), and a majority had tried to loose weight in the past 12 months (61%, 70% and 73% respectively). One third of obese individuals reported changing their eating habits in the past 12 months for medical reasons and 65% reported being less active than 10 years earlier. Individuals who were obese were more likely to report fair or poor health and were more likely to be women, African American and Mexican American, and have less than a high school education (p < 0.001). CONCLUSION: The vast majority of obese individuals consider themselves overweight and would like to weigh less. However, only one third of obese individuals had tried to change their eating habits in the past year and many reported less physical activity than 10 years earlier. BACKGROUND: Limited research has been done to validate the accuracy of self-report of chronic disease where computerized administrative databases are used to extract clinical information. Our objective was to validate the accuracy of self-reported diabetes among Veteran Affairs (VA) patients. METHODS: We conducted a cross-sectional analysis of baseline data collected for the Ambulatory Care QUality Improvement Project (ACQUIP). Eligible participants were sent à`H ealth Checklist'' that identified common chronic medical conditions. Seattle respondents for whom laboratory, clinical data and pharmacy data were available were selected for the validation study. Diabetes was defined by self-report (SR) or by having one or more of the following present: an ICD-9 code for diabetes (250.XX), medial record diabetes diagnosis, diabetic medication prescription (insulin or oral hypoglycemic agents), or diabetes specific laboratory data (fasting plasma glucose >126 mg/dL, random glucose >200 mg/dL or HbA1c >7.0%). Using ICD-9 codes as the gold standard, validity of SR was assessed. RESULTS: Of the 90,062 veterans enrolled in ACQUIP, screening questionnaires were sent to 11,392 Seattle VA patients. Of those, 6,995 (61%) returned the health checklist; diabetes SR occurred in 1625 (23.2%). For diabetic respondents, the positive predictive value of SR was 87.8% compared to ICD-9 code. Compared to those for whom diabetes was validated (true positives [TP]), those for whom diabetes was not validated (false positives [FP] and false negatives [FN] ) had similar demographic characteristics but had a higher proportion of surveys completed by proxy, more comorbid conditions and a higher proportion with hemoglobin A1c >8%. Determination of the kappa statistic between SR and ICD-9 diagnosis of diabetes was 0.84 (p < 0.001). Use of a laboratory test (k = 0.73, p < 0.001) or diabetic prescriptions (k = 0.82, p < 0.001) instead of SR decreased the kappa slightly. Addition of diabetic medications (k = 0.84, p < 0.001), laboratory tests (k = 0.78, p < 0.001) or the combination of the two (k = 0.78, p < 0.001), did not improve the kappa. CONCLUSION: SR of diabetes has excellent correlation with clinical diagnosis of diabetes. Addition of laboratory or medication data may help to ascertain false positives. BACKGROUND: The Joint Commission on Accreditation of Healthcare Organizations ( JCAHO) and other organizations have emphasized the importance of physician awareness of patients who suffer chronic pain. This study was designed to measure pain in a group of these patients and to identify associations with worsening perceptions of pain amenable to intervention. METHODS: Patients, with >3 months of pain, presenting to primary care clinics at 12 U.S. institutions, completed a verbally administered survey. After completion of the survey and visit with their doctor, their doctor completed a survey about the patient's pain. Bivariate analyses examined associations between patient characteristics, co-morbid illness, use of complimentary therapies, pain clinic utilization, and pain perception as interpreted by both patient and MD. A multivariate analysis of significant data (p < 0.2) was performed to control for potential confounders. RESULTS: Data were based on 345 patient and physician surveys. The mean patient age was 53 years (23±87). Sixty-eight percent were female and 45% were white. Participants averaged 3 co-morbid diseases and the mean pain perception on a pain scale from 0±10 was 6.7 (st.dev = 2.4). Bivariate analyses demonstrated a relationship between the following variables and the patient's pain rating: Pt-physician discordance in pain rating Corr = .61 Sees same doctor at visits(continuity) P < .004 Depression P < .0000 Pt feels disabled from pain P < .005 Seen by pain clinic/specialist P < .03 Race (black vs. white) P < .006 Physical Therapy P < .02 In the linear regression, perception of pain was associated with discordance in pain rating between physician and patient, use of a pain clinic, use of alternative medicine, concomitant depression, discontinuity of care, and patient feelings of disability due to pain (P < .05). The R-squared equaled .44. CONCLUSION: These results point to several potentially reversible components of more severe chronic pain. For example, depression is amenable to therapy, discordance could be addressed through enhanced communication, and continuity of care could be prioritized. The actual effect of such interventions of pain scores should be studied. BACKGROUND: Despite the overwhelming evidence from several randomized controlled trials that beta-blocker (BB) therapy for acute myocardial infarction (AMI) decreases mortality and reinfarction, studies have repeatedly demonstrated under-use of BB. Like previous studies, our group, the Michigan State University Institutional Collaborative Heart (MICH) Study Group, 1994±1995 (Phase 1) found underutilization of BB in patients following AMI in five mid-Michigan community hospitals. Since this initial study, several initiatives, including the Michigan Peer Review Organization (MPRO), were set up to improve the quality of care and use of appropriate evidenced based medications following AMI. The objective of this study was to determine if rate of BB use on admission, in hospital, and at discharge increased between Phase 1 and Phase II (1997) in patients with AMI. METHODS: We enrolled and reviewed the charts of all patients prospectively identified with AMI in Phase I (n = 1,163) and in Phase II (n = 508) in five mid-Michigan community hospitals. Exclusion criteria included chronic obstructive pulmonary disease, congestive heart failure, left ventricular ejection fraction <35, complete heart block, pulse <60, and use during the hospitalization of an intraaortic balloon pump or pressors for hypotension. We compared the use of BB in the two cohorts. RESULTS: Prescription of BB to ideal patients with AMI increased in-hospital (53.8 % vs. 72.8%; p < 0. 001) and at discharge (33.6% vs. 61.7%; p < 0.001) . No change was observed on admission among patients with previous AMI (25.9 vs. 25% p > 0.40). Logistic regression analysis did not identify race or sex as predictors of BB use. Younger age predicted BB use inhospital (OR 8.26, 95% CI 1.85±36.75 ) and at discharge. (OR 2.84, 95% CI 1.11±7.26) . CONCLUSION: BB use in-hospital and at discharge improved over the study period. However, improvement to 100% should be achieved in these ideal BB candidates. Lack of improvement in secondary prevention is suggested by no change in use among patient with previous AMI on arrival to the hospital. There still remains the need to improve the use of this relatively inexpensive but efficacious modality. Initiatives to improve use of BB after discharge and among elderly patients with AMI are urgently needed. METHODS: Using automated data sources available within a large health system, we identified patients with DMII who were continuously enrolled in the health plan and treated with metformin during the period 1999±2001. Among patients who met these criteria, we selected a random sample of 663 patients among whom information on both adherence to metformin, and glycosylated hemoglobin (HbA1c) and low density lipoprotein (LDL) levels, were measured. In the subset of patients who also were being treated with lipid lowering drugs, adherence to lipid medication was measured. Adherence was measured as 1-(the ratio of the number of gaps in days supplied/the number of days of observation). Mean and median adherence levels were estimated, and Wilcoxon and Spearman Correlation tests were used to assess the association of adherence to clinical outcomes. Linear regression models were used to adjust for socio-demographic characteristics. RESULTS: As shown in the BACKGROUND: Many studies suggest that people who report moderate consumption of alcohol (1±2 drinks/day) have lower coronary heart disease event rates than those who report none. This association may represent a protective effect of alcohol against atherosclerosis, protection against some other process causing acute coronary events (thrombosis, inflammation), or confounding by social correlates of alcohol use. To clarify these relationships, we measured the association between alcohol consumption and coronary calcification, a surrogate for atherosclerosis. METHODS: We used cross-sectional data collected in year 15 of CARDIA, a prospective study of African-American and Caucasian women and men aged 18±30 years at enrollment in 1985±1986. We compared the prevalence of coronary calcification in persons consuming different quantities of alcohol, and used logistic regression analysis to adjust for possible confounders (age, gender, race, smoking, income, education, and physical activity) and possible mediators of coronary artery disease (blood pressure, lipids, diabetes, body mass index, C-reactive protein, and fibrinogen). RESULTS: The 3037 CARDIA participants with coronary calcium measurements were on average 40.3 3.6 years old, 45% female, and 45% African-American. Alcohol consumption was light to moderate (see Table) . There was a strong, direct association between the amount of alcohol consumed and the prevalence of coronary calcification, even after adjustment for possible confounders and mediators of coronary artery disease (see Table) . Adjusting for confounders but not mediators yielded similar results. Race/sex specific analyses yielded no additional findings. CONCLUSION: The association we observed between moderate alcohol consumption and coronary calcium does not support a protective effect on this outcome, and in fact suggests the opposite.
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Prevalence of coronary calcification (CC) according to alcohol consumption (in drinks/day), crude and adjusted BACKGROUND: Obesity is a strong risk factor for cardiovascular disease (CVD) and allcause mortality. Long term success at weight loss is seldom achieved. This study used the Third National Health and Nutrition Examination Survey (NHANES III) to determine the relationship between self-recognition of obesity and prior attempts at weight loss. METHODS: 20,050 adults were surveyed in NHANES III. Data on 10,556 adults with body mass index (BMI) ! ! ! ! 25 were analyzed. Self-recognition of obesity was defined as selfclassification as``overweight'' by people with BMI ! ! ! ! 25. Prior weight loss attempt was defined by self-report of a weight loss attempt within the past 12 months. CVD-related comorbidities were defined as self-report of a physician diagnosed condition including diabetes mellitus, hypertension, high cholesterol, congestive heart failure, myocardial infarction or stroke. Number of comorbidities was categorized as none, 1, 2, and ! ! ! !3. The transtheoretical model of change (TTMC) was the theoretical framework of the study. We defined``contemplation'' as self-recognition of obesity and``action'' as prior weight loss attempt. We determined the proportion of patients with self-recognition of obesity and prior weight loss attempts across covariates (sex, age, race, education, income, employment status, marital status, health insurance status, perceived health status, BMI and number of CVD comorbidities) using 2 statistics. We used multiple logistic regression to determine the independent association between self-recognition of obesity and prior weight loss attempt while controlling for covariates. We used STATA to account for the complex survey design of NHANES III. RESULTS: 66% of overweight patients and 92% of obese patients correctly classified themselves as overweight. 45% of overweight patients and 64% of obese patients reported prior weight loss attempts. 62% of patients with self-recognition of obesity reported prior weight loss attempts compared with 21% of patients without recognition of obesity (p<0.0001). After controlling for covariates, self-recognition of obesity was independently associated with prior weight loss attempts (OR 4.86, 95% CI 3.66±6.45 BACKGROUND: Ineffective patient self-management, lack of knowledge of signs of worsening CHF, and consequently acute CHF exacerbations contribute to CHF-related morbidity and costs. We developed an interactive voice recognition (IVR) system so that patients could transfer CHF diary information into a central database which was regularly profiled. Patients with signs of worsening CHF were contacted by a nurse care manager for assessment and follow-up. Patients could listen to and request printed copies of CHF-related health information. The principal objective of this study was to assess the impact of this disease management program on patient self-management, knowledge, quality of life (QoL), and risk of acute CHF exacerbations. METHODS: CHF patients 30 years of age and older as of September 2001 (N = 728) were invited to participate. 106 patients consented and were randomized into a``telecare'' group (N = 64) and a usual care group (N = 42). On study entry and exit (6-months later), patients were surveyed by. Multi-item scales for CHF self-management practices, knowledge of signs of worsening CHF, frequency of CHF symptoms, and QoL were computed from survey responses. ED visits or hospital admissions indicative of worsening CHF (e.g. SOB, painful respiration) for the 6-month periods preceding and following study entry dates were collected from computerized databases. RESULTS: 47% of the study population was 65 years or older; 48% were female. At baseline, telecare and usual care groups did not differ (alpha = 0.05) in demographic or clinical characteristics, frequency of CHF symptoms, knowledge of CHF symptoms, self-management practices, QoL, or rate of acute exacerbation in the prior 6-months. Compared with usual care, the telecare group significantly improved CHF self-management practices (p = 0.02); however, neither improvement in knowledge of CHF symptoms or frequency of CHF symptoms nor reduction in acute exacerbations over the 6-month study period were obtained. Compared with usual care, compliant telecare patients (N = 27) realized significant improvements in both CHF self-management practices (p = 0.01) and some improvement in knowledge of symptoms of worsening CHF (p = 0.09). Compared with noncompliant telecare patients, compliant telecare patients also achieved reduction in risk of acute CHF exacerbations (p = 0.04) in the 6-month intervention period relative to the 6-month period prior to study entry. CONCLUSION: Compared with usual care, telecare patients only improved CHF selfmanagement practices over a 6-month period. Compliant telecare patients obtained additional benefits of improved knowledge of symptoms of worsening CHF and reduction in risk of acute CHF exacerbations. Telecare is an effective complement to usual CHF care for changing patient behavior and outcomes among patients who comply with the intervention protocol. BACKGROUND: Disease management programs improve outcomes for patients with Type 2 diabetes. Few programs however, have (1) focused on patients with significant barriers to care, (2) used clinical pharmacists to provide care, and (3) addressed cardiovascular risk reduction. METHODS: We performed a randomized controlled trial of a pharmacist-led, diabetes disease management program for patients with poor glucose control. Adult patients, followed for their diabetes care in our general medicine practice, who had HbA1C ! ! ! ! 8.0% were eligible. Participating patients were randomized to the intervention or usual care. The intervention includes (1) one-on-one educational sessions with a clinical pharmacist; (2) evidence-based treatment algorithms and a proactive computer system to manage glucose, blood pressure, cholesterol and aspirin use; and (3) frequent phone follow-up. Control patients received a onehour education session from the pharmacist, and usual care from their primary provider. Outcomes include HbA1c, blood pressure, lipid levels, and aspirin use at 6 and 12 months. RESULTS: From February 2001 to April 2002, we enrolled and randomized 218 patients. All patients have completed 6-month follow-up and complete data are available for 206 (94%). To date, 152 (70%) patients have completed 12-month follow-up. Mean age is 55 years, 56% are female, 65% African American, and 72% report income under $20,000 per year. Mean duration of diabetes is 8.4 years. At baseline, average HbA1c was 10.8% and systolic blood pressure (SBP) was 139. At 6 month follow-up, HbA1c improved by 2.6% points in the intervention group compared to 1.9% points in the control group (difference 0.7% points, 95% CI À0.08, 1.51); SBP decreased by 6.6 mmHg in intervention patients compared to a 3.5mm Hg increase in controls (difference 10.2 mmHg, 95% CI 3.2, 17.1), and 81% of intervention patients were on aspirin for cardiovascular risk reduction, compared to 55% of control patients (p < 0.001). At 12 month follow-up to date: HbA1c improved by 2.3% points in the intervention group compared to 1.5% points in the control group (difference 0.8% points, 95% CI À0.09, 1.73); SBP decreased by 4.9 mmHg in intervention patients compared to an increase of 2.2mm Hg in controls (difference 7.1mm Hg, 95% CI À0.5, 14.8), Total cholesterol/HDL ratio improved by 0.7 compared to 0.3 in the control group (difference 0.4, 95% CI À0.1, 1.0), and 79% of intervention patients were on aspirin compared to 55% of control patients (p < 0.01). CONCLUSION: A primary care-based, pharmacist-led disease management intervention is effective in improving clinical outcomes and reducing cardiovascular risk in patients with diabetes. Mean age was 55 years, 56% were female, 65% African American, and 72% report income under $20,000 per year. Average HbA1c at enrollment was 10.8%, and mean duration of diabetes was 8.4 years. On the REALM, 38% of patients had low literacy. Baseline demographics, literacy status, disease status, and clinical outcome measures were similar in both control and intervention groups. At 6 months follow-up, among control patients (n = 100), only 6% of patients with low literacy had met goal HbA1c (! ! ! !7.0%) compared to 24% of higher literacy patients (difference 17%, 95% CI 4%, 30%). Among intervention patients (n = 106), 36% of low literacy patients and 28% of higher literacy patients met goal HbA1c (difference À8%, 95% CI À27%, 9%). In logistic regression analysis, control patients with higher literacy were significantly more likely than patients with low literacy to obtain goal HbA1c at 6 months when adjusted for potential confounders such as baseline HbA1c, race, gender, and insulin use or duration of disease (Adjusted OR 5.6 95% CI 1.1,27.6). ), non-amputees (16.2 m < amputees), non-self-testers (29.9 m < frequent testers), the more educated (>4 years college 6.8 m < high school or less), and Ws (15.1 m < AAs) independently spent less total time (p < .1). CONCLUSION: Patients spent a highly variable amount of time on self-care activities and 1/ 3±1/2 spent no time on at least one important element of care. W race and non-self-testing were consistent independent predictors of spending no or less time. Asking patients about time spent on self-care is feasible and yields important information for clinicians and population health managers. BACKGROUND: There is growing theoretical and evidence-based support for the continued use of oral medication in the context of insulin therapy for type-2 diabetes. The objective of this study was to use existing national databases to investigate the extent of use of insulin/oral combination therapy, changes in its use with time, and characteristics of individuals most likely to be treated with combination therapy. METHODS: Data were extracted from the NHANES III (1988±1994) and NHANES IV (1999±2001) databases. Adults with diabetes diagnosed at age > 30 and not during pregnancy were considered to have type-2 diabetes. These populations were characterized and compared based on clinical and demographic parameters and diabetes treatment regimen. RESULTS: The NHANES III and IV study populations are considered representative of the noninstitutional US population. Using the NHANES weighting algorithm, the 1158 diabetic patients in NHANES III and the 383 in NHANES IV thus represent an increase in the number of type-2 diabetics in the US from 8 to 10.4 million between the two study periods. Over this time, average glycemic control (HbA1c 7.7% vs. 7.8%), blood pressure (SBP 137 vs. 135), and prevention of retinopathy (15.6% vs. 30.0%) have not improved. Treatment of hypercholesterolemia in diabetic patients has improved (total cholesterol 224 vs. 203 mg/dl). The percentage of diabetic patients treated with insulin/oral combination therapy has increased from 2.9% to 11.2%. In NHANES IV, individuals with diabetes complicated by hypertriglyceridemia (>200 mg/dl) or retinopathy were more likely to be on insulin/oral combination therapy (19% vs. 4.27% and 16.8% vs. 8.8%, respectively) . CONCLUSION: The percentage of diabetic patients on insulin/oral combination therapy has increased between the NHANES III and IV study periods, but still represents a small percentage of the total diabetic population. This is despite the fact that average glycemic control continues to be below that recommended for prevention of microvascular complications. Overall, patients with complicated diabetes are more likely to be on insulin/oral combination therapy. With the growing evidence-based and theoretical support for insulin/oral combination therapy, it is likely that this option should and will continue to be used more widely in the future. BACKGROUND: The increased risk for fractures associated with chronic steroid use results in increased morbidity and healthcare utilization. We selected this common problem to evaluate the benefits of developing a pharmacoepidemiology database using the Veterans Integrated Service Network of New England (VISN 1). This study describes the methods for developing this database and the scope of the problem of steroid induced fractures. METHODS: The unvalidated database was established using VISN 1 inpatient, outpatient administrative treatment and pharmacy files between January 1998 and November 2001. Prednisone comprised >80% of the VA steroid prescriptions and was used to define steroid users. All other steroid users were included with the non-steroid users. Chronic and occasional prednisone users were defined as individuals prescribed prednisone for >= 3 months or <3 months during any 12 month period, respectively. Individuals were identified by ICD-codes for fractures occurring after prednisone use and for the occurrence of a fracture and a diagnosis of osteoporosis. Differences between groups were determined by Chi-square analysis and are reported as relative risks (RR) with 95% confidence intervals (CI). Mantel-Haenszel chi-square test for trend was used to the determined the presence of a linear trend in risk for fracture in the three groups (chronic versus occasional prednisone use versus no prednisone use). RESULTS: 12,780 individuals out of 203,170 VA pharmacy users were identified as receiving a prescription for prednisone (37.9% chronic user, 62.1% occasional user). The occurrence of fractures in the prednisone group compared to all other VA pharmacy users was 3.48% versus 2.98% (RR 1.17; CI 1.06±1.20). There were more fractures among chronic prednisone users compared to non-users (RR 1.35 95% CI 1.17±1.55). There was a significant trend in the risk for fractures among chronic and occasional prednisone users versus non-users (p < 0.001). The diagnosis of both fracture and osteoporosis was also common among prednisone users and even greater among chronic users (RR 4.43 95% CI 3.40±5.83 and RR 7.63 95% CI 5.60±10.41, respectively) . The test for trend comparing non-prednisone users and chronic or occasional prednisone users was again significant (p < 0.001). CONCLUSION: The common occurrence of fractures among individuals using prednisone is similar to other published reports. Establishment of a VA pharmacoepidemiology database with well-defined methods enabled us to detail the magnitude of risk in our patient population. Use of such a database will help define problem areas and allow for the assessment of the appropriateness and successfulness of preventive interventions. BACKGROUND: Recent changes in the prescribing guidelines of simvastatin reflect the concern over the potential for rhambdomyolysis and myositis when simvastatin is used in combination with certain drugs, particularly those metabolized by the CYP3A4 system. We sought to describe the concomitant use of these therapies in the Veterans Intergrated Service Network of New England (VISN 1). METHODS: We conducted a retrospective analysis of the concomitant use of simvastatin with inhibitors of the CYP3A4 enzyme system or drugs known to increase the risk for rhambdomyolysis and myositis. We identified individuals prescribed simvastatin, cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, nefazadone, protease inhibitors, gemfibrozil, fenofibrate, niacin, amiodarone, verapamil, and diltiazem between August, 1997± November, 2001 . For each prescription, length of time on therapy was established by calculating a``start'' date and``stop'' date based on the date the prescription was filled and 1.5 times the days supply. The entire study period was divided into 104 two-week time intervals. Concomitant therapy was determined based on the occurrence of prescriptions for both simvastatin and interacting medications appearing in the same 2-week interval. RESULTS: Among the 203,170 VA pharmacy users in VISN 1, 33,628 (17%) received a prescription for simvastatin. The average initial dose was 23.6 mg, which increased to 28.9 mg over time. Twenty-five percent of simvastatin users were also taking one or more drugs known to increase the risk for complications. Among simvastatin users, diltiazem was prescribed most frequently (8.7%). Other common concurrent prescriptions included gemfibrozil (6.4%), verapamil (3.4%), ketoconazole (2.5%), niacin (2%), erythromycin (1.8%), amiodarone (1.5%), nefazodone (1.5%), and clarithromycin (0.6%). 3.5 percent were receiving 2 or more of these drugs in addition to simvastatin. CONCLUSION: Concurrent prescribing of drugs that increase the likelihood for rhambdomyolysis and myositis is common in the VA. Based on estimates of VA users along with extrapolation of the percent of statin use throughout the VA, there are likely 700,000 to 1 million users of simvastatin with approximately 140,00±200,000 individuals using concomitant therapies nationally. This study raises several issues regarding how best to balance the risk and benefits of statin therapy particularly in an elderly patient population with numerous comorbidities. BACKGROUND: The association between obesity and diabetes mellitus is well established. Several studies have shown that patients with diabetes have a much higher mortality rate than that of their non-diabetic counterparts. Yet, little is known about specific risk factors for total and cardiovascular mortality in a diabetic population, even for body mass index (BMI). METHODS: From the enrollment cohort of 104,353 men from the Physicians' Health Study, 4,221 had diabetes at baseline. Of these men, 2,681 provided information about their BMI and other coronary risk factors and were free from myocardial infarction, stroke, cancer, and liver disease. Using Cox proportional hazards, we evaluated for an association between BMI and both all-cause mortality and cardiovascular mortality. BACKGROUND: Diagnostic criteria for high utilizing patients (HUP) with medically unexplained symptoms (MUS) stem entirely from DSM-IV. We evaluated primary care MUS patients without DSM-IV Somatoform diagnoses. METHODS: We identified a random sample of HUP (2 or more consecutive years) with MUS using a systematic, reliable chart rating method and obtained their DSM-IV somatoform diagnoses via the Composite International Diagnostic Interview. We then compared those with any somatoform diagnosis (``DSM-positive''), full or abridged, to those without one (``DSM-negative'') and to population normals on No trial exclusively enrolled patients with pulmonary emboli (PE) although patients with PE were included in 8 of the 13 studies. The durations of warfarin therapy ranged from 30 to 1460 days. 3 studies evaluated treatment after a first episode of VTE. The monthly rates of recurrent deep venous thrombosis (DVT) between 6-weeks and 6-months were lower with warfarin than with placebo (0.5% vs 2.2%/month) in 1 study, but cumulative DVT recurrence rates were comparable in the groups treated for 3 months and 6 months in another study (7% vs. 6%).Warfarin treatment beyond 3 months was associated with more major bleeding in all three studies. The only trial that compared prolonged warfarin treatment after a second DVT to six months of therapy demonstrated recurrence rates of 3% vs.18%, with major bleeding rates of 9% and 3%, respectively, at 4 years of follow-up. In two subgroups with calf DVT, no difference was found in recurrence rates with 6-weeks compared to 3-months of treatment, although withholding warfarin entirely resulted in high recurrence rates (34% vs. 4% with 3-months of warfarin). Four studies of subgroups of patients with transient risk factors demonstrated low rates of recurrence with short durations of therapy. CONCLUSION: The evidence suggests that the optimal duration of therapy depends on the location and circumstances initiating the thrombosis. Limited evidence is available to guide management of patients with known thrombophilia. BACKGROUND: The prevalence of Hepatitis C is about 1.8 % nationwide, and 3±5 % in primary care settings. It is estimated that half of patients with chronic Hepatitis C have not been identified, and minority populations carry a disproportionate burden of this disease. Routine screening for Hepatitis C antibody is not cost effective, and there is no published validated instrument to screen patients at high risk for Hepatitis C. Our aims were to: 1) Develop and validate an English/Spanish Hepatitis C Screening Instrument for use in an urban, minority, primary care population. 2) Determine the prevalence of Hepatitis C antibody in an East Harlem hospital-based primary care practice. METHODS: The questionnaire has 27 items, based on reported risk factors in the literature, and is divided into domains: 7 item Occupational, 8 item Medical History, 3 item General Exposure, 4 item Personal Care, 5 item Risk Behavior/Situations. Adult patients waiting to be seen by a provider were randomly selected to complete the questionnaire anonymously, and have a blood test for the Hepatitis C antibody. RESULTS: We report on the first 565 of a total of 1,000 patients to be screened. The refusal rate was 41%. Demographics among the 565 screened: 70% female; 57% born in the US and 27% in Puerto Rico. Racially, 36 % were African-American, 49% Hispanic, 11% White, 4% other.
A LONGITUDINAL ANALYSIS OF THE
OCCURRENCES OF CONCOMITANT USE OF SIMVASTATIN WITH DRUGS
HEPATITIS C PREVALENCE AND RISK FACTORS IN AN EAST
Ethnically, 47% considered themselves to be non-Hispanic, 37% Puerto Rican, 4% Dominican and 12% other Hispanic. Insurance: 48% Medicaid, 6 % Medicaid HMO, 21% Medicare, 18% private, 7% other. Hepatitis C results: 9.2 % antibody positive, and for 29% of these, it was a new diagnosis. The only demographic factor that was associated with having Heptitis C was a lower educational level (chi-square 14.26, significance .075). Neither ethnicity, insurance status, country of birth, or primary language had any correlation with Hepatitis C status. The following questionnaire items were significantly associated with Hepatitis C positivity. Those marked * remained independent predictors in multiple logistic regression analysis. CONCLUSION: The prevalence of Hepatitis C in our hospital-based East Harlem primary care practice is significantly higher than that reported in previous studies. This is in part likely due to our sicker patient base, and high proportion of economically disadvantaged patients. An analysis of the full cohort will allow us to streamline the risk questionnaire, for future incorporation into general primary care practices.
Questionnaire items associated with Hepatitis C antibody positivity BACKGROUND: Injection drug use (IDU) accounts for 60% of new hepatitis C infections (HCV) and alcohol consumption worsens hepatic function in HCV. The NIH has historically recommended 6 months of abstinence prior to interferon (IFN) treatment of HCV. Since combined treatment of substance use disorders (SUDs) and HCV may decrease transmission and preserve hepatic function, this analysis was designed to explore the prevalence of SUDs amongst patients with newly-diagnosed chronic HCV in relation to eligibility for IFN treatment. METHODS: We performed a cross-sectional analysis of data from the New Haven County Liver Study, which identified newly-diagnosed chronic liver disease (CLD) patients from 19 gastroenterology practices from 2/98 through 11/02. Data were collected by chart review, laboratory assessment, and patient interview. All patients met criteria for CLD through abnormal lab, biopsy, radiologic finding, or clinical event. SUDs history included lifetime and recent IDU (within an estimated 2 years) and current alcohol consumption. We defined at-risk alcohol consumption according to NIAAA criteria. We then applied the 1997 NIH eligibility criteria, excluding biopsy and imaging data, to patients with serologically-confirmed HCVinduced CLD to determine the prevalence of conditions that would exclude patients from IFN treatment. Finally, we examined the independent impact of SUDs on IFN eligibility. RESULTS: Of the 468 subjects who were identified as having CLD, 291 (62%) met criteria for HCV-induced disease. The 291 subjects had a mean age of 45 years (19±82), 188/291 (64%) were male, and 243/291 (84%) were white. One hundred and eighty-five of 290 (64%) reported lifetime IDU, 21/285 (7%) with recent IDU, and 29/287 (10%) with at-risk alcohol consumption. Applying the NIH eligibility criteria, 213/291 (73%) may have been ineligible for IFN treatment. One hundred and thirty-five of 291 (46%) might have been excluded due to medical conditions, 64/291 (22%) due to normal ALT levels or negative HCV RNA, 47/291 (16%) due to psychiatric diagnoses, 21/285 (7%) due to recent IDU, and 29/287 (10%) due to at-risk alcohol consumption. Overall, 28/291 (10%) subjects might have been excluded on the basis of recent SUDs alone. CONCLUSION: Many patients with newly-diagnosed chronic HCV appear to be ineligible for IFN treatment. Revised NIH guidelines advocate concurrent treatment for SUDs and HCV. The proportion of these patients with recent SUDs represent a potentially treatable group who are at high risk for transmitting and experiencing the long-term complications of this major cause of CLD.
A RANDOMIZED TRIAL OF PAROXETINE FOR THE IRRITABLE BOWEL SYNDROME. BACKGROUND: Selective serotonin reuptake inhibitors have been recommended for use in the treatment of IBS although their role has not been studied in a systematic manner. The role of dietary fiber is controversial. We evaluated the effectiveness of paroxetine with high fiber diet (HFD) and HFD alone for the treatment of patients with IBS. METHODS: Seventy-two women and 28 men with symptomatic IBS (by Rome Criteria) were enrolled through community advirtising. Candidates with a history of depression were excluded. Patients meeting IBS criteria were divided into two groups at entry: Group A
